CNumberInhibitorBruttoMWActionReferenceReference 2PatentCommercial VendorCASInChIInChI KeyPubChem CIDSMILES
177(5Z)-7-OxozeaenolC19H22O7362.37TAK1Ninomiya-Tsuji (2003) J.Biol.Chem. 278 18485Windheim et al (2007) Biochem.J. 404 179Tocris66018-38-0InChI=1S/C19H22O7/c1-11-5-3-7-14(20)18(23)15(21)8-4-6-12-9-13(25-2)10-16 (22)17(12)19(24)26-11/h3-4,6-7,9-11,15,18,21-23H,5,8H2,1-2H3NEQZWEXWOFPKOT-UHFFFAOYSA-N53442201CC1CC=CC(=O)C(C(CC=CC2=CC(=CC(=C2C(=O)O1)O)OC)O)O
21 NA-PP1 (PP1 Analog)C19H19N5317.4SrcBishop A. C. (2000) Nature 407 395Bishop A.C. (1999) J. Am. Chem. Soc. 121 627WO2003082341Merck (Calbiochem)221243-82-9InChI=1S/C19H19N5/c1-19(2,3)24-18-15(17(20)21-11-22-18)16(23-24)14-10-6-8-12-7-4-5-9-13(12)14/h4-11H,1-3H3,(H2,20,21,22)XSHQBIXMLULFEV-UHFFFAOYSA-N4877CC(C)(C)N1C2=C(C(=N1)C3=CC=CC4=CC=CC=C43)C(=NC=N2)N
31 NM-PP1 (PP1 Analog II)C20H21N5331.4SrcIra G. (2004) Nature 431 1011 Papa F.R. (2003) Science 302 1533WO2000042042Merck (Calbiochem)221244-14-0InChI=1S/C20H21N5/c1-20(2,3)25-19-17(18(21)22-12-23-19)16(24-25)11-14-9-6-8-13-7-4-5-10-15(13)14/h4-10,12H,11H2,1-3H3,(H2,21,22,23)GDQXJQSQYMMKRA-UHFFFAOYSA-N5154691CC(C)(C)N1C2=C(C(=N1)CC3=CC=CC4=CC=CC=C43)C(=NC=N2)N
2932-AminopurineC5H5N5135.1267PKRSigma452-06-2InChI=1S/C5H5N5/c6-5-7-1-3-4(10-5)9-2-8-3/h1-2H,(H3,6,7,8,9,10)MWBWWFOAEOYUST-UHFFFAOYSA-N9955C1=C2C(=NC(=N1)N)N=CN2
5A-443654C24H23ON5x2HCl470.39Akt1Shi Y. (2005) Neoplasia 7 992-1000.WO2007106884AdooQ Bioscience552325-16-3InChI=1S/C24H23N5O/c1-15-22-10-16(6-7-24(22)29-28-15)17-9-20(13-26-11-17)30-14-19(25)8-18-12-27-23-5-3-2-4-21(18)23/h2-7,9-13,19,27H,8,14,25H2,1H3,(H,28,29)/t19-/m0/s1YWTBGJGMTBHQTM-IBGZPJMESA-N10172943CC1=C2C=C(C=CC2=NN1)C3=CC(=CN=C3)OCC(CC4=CNC5=CC=CC=C54)N
6A-769662C20H12N2O3S360.39AMPK ActivatorCool B. (2006) Cell Metabolism 3 403-416US7119205Tocris844499-71-4InChI=1S/C20H12N2O3S/c21-9-14-18(24)17-15(10-26-20(17)22-19(14)25)12-7-5-11(6-8-12)13-3-1-2-4-16(13)23/h1-8,10,23H,(H2,22,24,25)CTESJDQKVOEUOY-UHFFFAOYSA-N54708532C1=CC=C(C(=C1)C2=CC=C(C=C2)C3=CSC4=C3C(=C(C(=O)N4)C#N)O)O
162A-83-01C25H19N5S421.52ALK5Tojo (2005) Cancer.Sci. 96 791Tocris909910-43-6InChI=1S/C25H19N5S/c1-17-8-7-13-23(27-17)24-21(19-14-15-26-22-12-6-5-11-20(19)22)16-30(29-24)25(31)28-18-9-3-2-4-10-18/h2-16H,1H3,(H,28,31)HIJMSZGHKQPPJS-UHFFFAOYSA-N16218924CC1=CC=CC(=N1)C2=NN(C=C2C3=CC=NC4=CC=CC=C34)C(=S)NC5=CC=CC=C5
144AG1296 (Tyrphostin)C16H14N2O2266.29PDGFKovalenko M. (1994) Cancer Res. 54 6106Merck (Calbiochem)146535-11-7InChI=1S/C16H14N2O2/c1-19-15-8-12-13(9-16(15)20-2)18-14(10-17-12)11-6-4-3-5-7-11/h3-10H,1-2H3QNOXYUNHIGOWNY-UHFFFAOYSA-N2049COC1=C(C=C2C(=C1)N=CC(=N2)C3=CC=CC=C3)OC
154AG1478 (Tyrphostin)C16H14ClN3O2315.75EGFROsherov N. (1994) A. Eur. J. Biochem. 225 1047Merck (Calbiochem)153436-53-4InChI=1S/C16H14ClN3O2/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11/h3-9H,1-2H3,(H,18,19,20)GFNNBHLJANVSQV-UHFFFAOYSA-N2051COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC
7AG490C17H14N2O3294.3EGFR, JAKJaleel M. (2004) Biochemistry 43 8247 Eriksen K.W. (2001) Leukemia 15 787WO2004052359Merck (Calbiochem)133550-30-8InChI=1S/C17H14N2O3/c18-10-14(8-13-6-7-15(20)16(21)9-13)17(22)19-11-12-4-2-1-3-5-12/h1-9,20-21H,11H2,(H,19,22)/b14-8+TUCIOBMMDDOEMM-RIYZIHGNSA-N5328779C1=CC=C(C=C1)CNC(=O)C(=CC2=CC(=C(C=C2)O)O)C#N
8AG879 (Tyrphostin)C18H24N2OS316.5Tyrosine-kinasesKonrad R.J. (1996) J. Biol. Chem. 271 24179Levitzki A. Gazit A. (1995) Science 267 1782WO2003068927Merck (Calbiochem)148741-30-4InChI=1S/C18H24N2OS/c1-17(2,3)13-8-11(7-12(10-19)16(20)22)9-14(15(13)21)18(4,5)6/h7-9,22H,20H2,1-6H3/b16-12+LCUMYVYIHXYBIA-FOWTUZBSSA-N5487525CC(C)(C)C1=CC(=CC(=C(N)S)C#N)C=C(C1=O)C(C)(C)C
148Akt Inhibitor IVC31H27IN4S614.6AktKau T. R. (2003) Cancer Cell 4 463Merck (Calbiochem)681281-88-9InChI=1S/C31H27N4S.HI/c1-3-34-28-22-23(31-32-26-16-10-11-17-29(26)36-31)18-19-27(28)35(25-14-8-5-9-15-25)30(34)20-21-33(2)24-12-6-4-7-13-24;/h4-22H,3H2,1-2H3;1H/q+1;/p-1NAYRELMNTQSBIN-UHFFFAOYSA-M5719375CC[N+]1=C(N(C2=C1C=C(C=C2)C3=NC4=CC=CC=C4S3)C5=CC=CC=C5)C=CN(C)C6=CC=CC=C6.[I-]
9Akti 1/2C34H29N7O551.6Akt1, Akt2Logie L. (2007) Diabetes 2218-27Barnett S.F. (2005) Biochem. J. 385 399WO2013147649Merck (Calbiochem)612847-09-3InChI=1S/C34H29N7O/c42-34-39-26-8-4-5-9-31(26)41(34)25-14-16-40(17-15-25)20-22-10-12-24(13-11-22)33-32(23-6-2-1-3-7-23)37-29-18-27-28(36-21-35-27)19-30(29)38-33/h1-13,18-19,21,25H,14-17,20H2,(H,35,36)(H,39,42)BIWGYFZAEWGBAL-UHFFFAOYSA-N10196499C1CN(CCC1N2C3=CC=CC=C3NC2=O)CC4=CC=C(C=C4)C5=NC6=CC7=C(C=C6N=C5C8=CC=CC=C8)N=CN7
10AlsterpaulloneC16H11N3O3293.3GSK3b, CDK5/p25, CDK1/cyclin BLeost M. (2000) Eur. J. Biochem. 267 5983Schultz C. (1999) J. Med. Chem. 42 2909EP20050109789Merck (Calbiochem)237430-03-4InChI=1S/C16H11N3O3/c20-15-8-12-11-7-9(19(21)22)5-6-14(11)18-16(12)10-3-1-2-4-13(10)17-15/h1-7,18H,8H2,(H,17,20)OLUKILHGKRVDCT-UHFFFAOYSA-N5005498C1C2=C(C3=CC=CC=C3NC1=O)NC4=C2C=C(C=C4)[N+](=O)[O-]
219Amgen TBK 1 inhibitor (Compound II)C28H35N7O4533.62TBK1Ou Y.H. (2011) Molecular Cell 41 458-470InChI=1S/C28H35N7O4/c1-33-11-13-34(14-12-33)10-5-15-39-25-17-21(16-24(37-3)26(25)38-4)31-28-29-18-20-19-30-35(27(20)32-28)22-6-8-23(36-2)9-7-22/h6-9,16-19H,5,10-15H2,1-4H3,(H,29,31,32)PVQUVXVUIZZLMP-UHFFFAOYSA-NCN1CCN(CC1)CCCOc2cc(cc(c2OC)OC)Nc3ncc4cnn(c4n3)c5ccc(cc5)OC
310Amgen-NIK-28C20H20N4O332.4NIKLi K. (2013) Bioorganic and Medicinal Chemistry Letters 23 1238-1244InChI=1S/C20H20N4O/c1-20(2,25)9-8-12-6-7-15-14(10-12)17-16(23-15)5-3-4-13-11-22-19(21)24-18(13)17/h6-7,10-11,23,25H,3-5H2,1-2H3,(H2,21,22,24)DGLFSNZWRYADFC-UHFFFAOYSA-NCC(C)(C#Cc1ccc2c(c1)c-3c([nH]2)CCCc4c3nc(nc4)N)O
311AmlexanoxC16H14N2O4 298.293TBK1, IKKeTocris68302-57-8InChI=1S/C16H14N2O4/c1-7(2)8-3-4-12-9(5-8)13(19)10-6-11(16(20)21)14(17)18-15(10)22-12/h3-7H,1-2H3,(H2,17,18)(H,20,21)SGRYPYWGNKJSDL-UHFFFAOYSA-N2161O=C1c3cc(ccc3Oc2nc(c(cc12)C(=O)O)N)C(C)C
11ARA014418C12H12N4O4S308.3GSK3Noble W. (2005) Proc. Natl. Acad. Sci. USA 102 6990Bhat R. (2003) J. Biol. Chem. 278 45937WO2013124413Sigma487021-52-3InChI=1S/C12H12N4O4S/c1-20-9-4-2-8(3-5-9)6-13-11(17)15-12-14-7-10(21-12)16(18)19/h2-5,7H,6H2,1H3,(H2,13,14,15,17)YAEMHJKFIIIULI-UHFFFAOYSA-N448014COC1=CC=C(C=C1)CNC(=O)NC2=NC=C(S2)[N+](=O)[O-]
12AS601245 (JNK Inhibitor V)C20H16N6S372.5JNKGaillard P. (2005) J. Med. Chem. 48 4596Carboni S. (2005) J. Neurochem. 92 1054WO2013152038Merck (Calbiochem)345987-15-7InChI=1S/C20H16N6S/c21-12-15(19-25-17-5-1-2-6-18(17)27-19)16-8-11-24-20(26-16)23-10-7-14-4-3-9-22-13-14/h1-6,8-9,11,13,25H,7,10H2,(H,23,24,26)/b19-15+AVLYNJZZQYEFEA-XDJHFCHBSA-N11422035C1=CC=C2C(=C1)NC(=C(C#N)C3=NC(=NC=C3)NCCC4=CN=CC=C4)S2
182AX 20017C13H16N2O2S264.34PknGWalburger A (2004) Science 304 1800-1804 Merck Millipore329221-38-7InChI=1S/C13H16N2O2S/c14-11(16)10-8-3-1-2-4-9(8)18-13(10)15-12(17)7-5-6-7/h7H,1-6H2,(H2,14,16)(H,15,17)VATFNEMGBRWLHI-UHFFFAOYSA-N673481C1CCC2=C(C1)C(=C(S2)NC(=O)C3CC3)C(=O)N
212AZD8055C25H31N5O4465.5mTOR C1, mTOR C2Chresta C.M. (2010) Cancer Res. 70 288-298Sini P. (2010) Autophagy 6(4)Selleck1009298-09-2InChI=1S/C25H31N5O4/c1-16-14-33-10-8-29(16)24-20-5-6-21(18-4-7-22(32-3)19(12-18)13-31)26-23(20)27-25(28-24)30-9-11-34-15-17(30)2/h4-7,12,16-17,31H,8-11,13-15H2,1-3H3/t16-,17-/m0/s1KVLFRAWTRWDEDF-IRXDYDNUSA-N25262965CC1COCCN1C2=NC(=NC3=C2C=CC(=N3)C4=CC(=C(C=C4)OC)CO)N5CCOCC5C
280BAY 61-3606C20H18N6O3 · xHCl · yH2O390.40SykYamamoto N. (2003) J. Pharmacol. Exp. Ther. 306 1174-1181Sigma732983-37-8InChI=1S/C20H18N6O3/c1-28-15-6-5-12(10-16(15)29-2)14-11-17-22-8-9-26(17)20(24-14)25-19-13(18(21)27)4-3-7-23-19/h3-11H,1-2H3,(H2,21,27)(H,23,24,25)JWQOJVOKBAAAAR-UHFFFAOYSA-N10200390COC1=C(C=C(C=C1)C2=CC3=NC=CN3C(=N2)NC4=C(C=CC=N4)C(=O)N)OC
14Bay 65-1942C22H26ClN3O4431.91IKKbZiegelbauer K. (2005) British Journal of Pharmacology 145 178-192 (compound A)Moss N.C. (2007) Am J Physiol Heart Circ Physiol 293 H2248-53AdooQ Bioscience600734-06-3InChI=1S/C22H25N3O4.ClH/c26-18-4-1-5-19(28-11-13-6-7-13)20(18)17-9-15(14-3-2-8-23-10-14)16-12-29-22(27)25-21(16)24-17;/h1,4-5,9,13-14,23-24H,2-3,6-8,10-12H2,(H,25,27);1H/b20-17-;/t14-;/m1./s1KSTOJOVDFHFWCE-VHNKIRJFSA-N66575052C1CC(CNC1)C2=CC(=C3C(=O)C=CC=C3OCC4CC4)NC5=C2COC(=O)N5.Cl
15BAY-11-7082C10H9NO2S207.2NFKBIAKamthong P.J. (2001) Biochem. J. 356Izban K.F. (2000) Hum. Pathol. 31 1482WO2003072038Merck (Calbiochem)19542-67-7InChI=1S/C10H9NO2S/c1-9-3-5-10(6-4-9)14(12,13)8-2-7-11/h2-6,8H,1H3/b8-2+DOEWDSDBFRHVAP-KRXBUXKQSA-N5353431CC1=CC=C(C=C1)S(=O)(=O)C=CC#N
16BAY439006 (Sorafenib, Nexavar)C21H16ClF3N4O3464.8RafLyons J.F. (2001) Endocrine Related Cancer 8 3 219-225Wilhelm S.M. (2004) Cancer Res. 64(19) 7099-109WO2002085857Axon284461-73-0InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)MLDQJTXFUGDVEO-UHFFFAOYSA-N216239CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
17BI 2536C28H39N7O3521.65PLK1Steegmaier M. (2007) Current Biology 17 316-322Axon755038-02-9InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1XQVVPGYIWAGRNI-JOCHJYFZSA-N11364421CCC1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C
131BI-78D3C13H9N5O5S2379.37JNKStebbins J.L. (2008) PNAS 105 16809-16813Merck (Calbiochem)883065-90-5InChI=1S/C13H9N5O5S2/c19-11-15-16-12(25-13-14-6-10(24-13)18(20)21)17(11)7-1-2-8-9(5-7)23-4-3-22-8/h1-2,5-6H,3-4H2,(H,15,19)QFRLDZGQEZCCJZ-UHFFFAOYSA-N2747117C1COC2=C(O1)C=CC(=C2)N3C(=O)NN=C3SC4=NC=C(S4)[N+](=O)[O-]
18BI-D-1870C19H23N5O2F2391.42RSKSapkota G.P. (2007) Biochem. J. 401 29–38WO2003020722Axon501437-28-1InChI=1S/C19H23F2N5O2/c1-10(2)5-6-26-11(3)18(28)25(4)15-9-22-19(24-17(15)26)23-12-7-13(20)16(27)14(21)8-12/h7-11,27H,5-6H2,1-4H3,(H,22,23,24)DTEKTGDVSARYDS-UHFFFAOYSA-N25023738CC1C(=O)N(C2=CN=C(N=C2N1CCC(C)C)NC3=CC(=C(C(=C3)F)O)F)C
201BI605906 (BIX02514)C17H22F2N4O3S2432.51IKKβClark K. (2011) Biochem. J. 434 93-104960293-88-3InChI=1S/C17H22F2N4O3S2/c1-3-17(18,19)10-8-11(23-6-4-9(5-7-23)28(2,25)26)22-16-12(10)13(20)14(27-16)15(21)24/h8-9H,3-7,20H2,1-2H3,(H2,21,24)IYHHRZBKXXKDDY-UHFFFAOYSA-NCCC(c1cc(nc2c1c(c(s2)C(=O)N)N)N3CCC(CC3)S(=O)(=O)C)(F)F
19BIO (6-Bromoindirubin-3'-oxime)C16H10BrN3O2356.2GSK3Tseng A.S. (2006) Chem. Biol. 13 957Polychronopoulos P. (2004) J. Med. Chem. 47 935WO2007016485Sigma667463-62-9InChI=1S/C16H10BrN3O2/c17-8-5-6-9-12(7-8)19-16(21)13(9)15-14(20-22)10-3-1-2-4-11(10)18-15/h1-7,20,22H,(H,19,21)/b15-13-WNWSUJQVZJJGLF-SQFISAMPSA-N5287844C1=CC2=C(C(=C3C4=C(C=C(C=C4)Br)NC3=O)N=C2C=C1)NO
20BIRB-0796 (Doramapimod)C31H37N5O3 527.66p38 MAPKRegan J. (2002) J. Med. Chem 45 2994-3008WO2004014387Axon285983-48-4InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H2,1-4H3,(H2,32,33,37)MVCOAUNKQVWQHZ-UHFFFAOYSA-N156422CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCCN5CCOCC5
21BlebbistatinC18H16N2O2292.3myosin IIShu S. (2005) Proc. Natl. Acad. Sci. USA 102 1472Kovacs M. (2004) J. Biol. Chem. 279 35557WO2012062819Merck (Calbiochem)674289-55-5InChI=1S/C18H16N2O2/c1-12-7-8-15-14(11-12)16(21)18(22)9-10-20(17(18)19-15)13-5-3-2-4-6-13/h2-8,11,22H,9-10H2,1H3LZAXPYOBKSJSEX-UHFFFAOYSA-N3476986CC1=CC2=C(C=C1)N=C3C(C2=O)(CCN3C4=CC=CC=C4)O
176BML-258 (SK1-I)C17H28ClNO2313.86SphK1Paugh S.W. (2008) Blood 112 1382-1391SuperNova Life Science1072443-89-0InChI=1S/C17H27NO2.ClH/c1-3-4-5-6-14-7-9-15(10-8-14)11-12-17(20)16(13-19)18-2;/h7-12,16-20H,3-6,13H2,1-2H3;1H/b12-11+;/t16-,17+;/m1./s1 SGCJOKUPGVFNKS-UUCPMUBFSA-NCCCCCc1ccc(cc1)/C=C/[C@@H]([C@@H](CO)NC)O.Cl
22BMS345541 (IKK Inhibitor III)C14H17N5255.32IKBKBDu Z. (2012) J Interferon Cytokine Res. 368-77DE4329970Merck (Calbiochem)547757-23-3InChI=1S/C14H17N5.ClH/c1-9-3-4-11-12(7-9)19-10(2)8-17-14(19)13(18-11)16-6-5-15;/h3-4,7-8H,5-6,15H2,1-2H3,(H,16,18);1HMIDKPVLYXNLFGZ-UHFFFAOYSA-N9926054CC1=CC2=C(C=C1)N=C(C3=NC=C(N23)C)NCCN.Cl
329BosutinibC26H29Cl2N5O3 530.45srcVultur A. Mol Cancer Ther. (2008) 1185-94WO2013024144Cayman Chemical380843-75-4InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)UBPYILGKFZZVDX-UHFFFAOYSA-N5328940CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC
23BX-320C23H31BrN8O3547.45PDK1Feldman R.I. (2005) Journal of Biological Chemistry 280 19867-19874WO2004048343SuperNova Life Science702676-93-5InChI=1S/C23H31BrN8O3/c1-23(2,19(25)33)20(34)27-10-6-9-26-18-17(24)14-28-21(31-18)29-15-7-5-8-16(13-15)30-22(35)32-11-3-4-12-32/h5,7-8,13-14H,3-4,6,9-12H2,1-2H3,(H2,25,33)(H,27,34)(H,30,35)(H2,26,28,29,31)ZNSULAZTNWFKEW-UHFFFAOYSA-N657138CC(C)(C(=O)N)C(=O)NCCCNC1=NC(=NC=C1Br)NC2=CC(=CC=C2)NC(=O)N3CCCC3
24BX-517C15H14N4O2282.3PDK1Islam I. (2007) Bioorganic and Medicinal Chemistry Letters 17 3814-3818CN102639566EMD MilliporeInChI=1S/C15H14N4O2/c1-8(11-3-2-6-17-11)13-10-7-9(18-15(16)21)4-5-12(10)19-14(13)20/h2-7,17H,1H3,(H,19,20)(H3,16,18,21)/b13-8-DFURSNCTQGJRRX-JYRVWZFOSA-N11161844CC(=C1C2=C(C=CC(=C2)NC(=O)N)NC1=O)C3=CC=CN3
25BX-517 Analog (compound 7b)C19H15N5O2345.35PDK1Islam I. (2007) Bioorganic and Medicinal Chemistry Letters 17 3819-3825InChI=1S/C19H15N5O2/c20-19(26)23-13-3-4-17-15(7-13)16(18(25)24-17)8-14-6-12(10-22-14)11-2-1-5-21-9-11/h1-10,22H,(H,24,25)(H3,20,23,26)/b16-8-XROQQHOCADBSBW-PXNMLYILSA-N11588244c1cc(cnc1)c2cc([nH]c2)/C=C\3/c4cc(ccc4NC3=O)NC(=O)N
26BX-795C23H26IN7O2S591.47PDK1Feldman R.I. (2005) Journal of Biological Chemistry 280 19867-19874WO2004048343Axon702675-74-9InChI=1S/C23H26IN7O2S/c24-18-15-27-22(30-20(18)25-9-5-10-26-21(32)19-8-4-13-34-19)28-16-6-3-7-17(14-16)29-23(33)31-11-1-2-12-31/h3-4,6-8,13-15H,1-2,5,9-12H2,(H,26,32)(H,29,33)(H2,25,27,28,30)VAVXGGRQQJZYBL-UHFFFAOYSA-N10077147C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCCNC(=O)C4=CC=CS4)I
320BX-912C20H23BrN8O471.35PDKFeldman RI. (2005) J. Biol. Chem. 2005 May 20 280(20) 19867-74Axon702674-56-4InChI=1S/C20H23BrN8O/c21-17-12-24-19(28-18(17)23-7-6-16-11-22-13-25-16)26-14-4-3-5-15(10-14)27-20(30)29-8-1-2-9-29/h3-5,10-13H,1-2,6-9H2,(H,22,25)(H,27,30)(H2,23,24,26,28)DMMILYKXNCVKOJ-UHFFFAOYSA-N11754511C1CCN(C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)NCCC4=CN=CN4)Br
136CaffeineC8H10N4O2194.19ATMIslam M.S. (1998) Proc. Natl. Acad. Sci. USA 95 6145-6150Sigma58-08-2InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3RYYVLZVUVIJVGH-UHFFFAOYSA-N2519CN1C=NC2=C1C(=O)N(C(=O)N2C)C
312CAY10576C22H19N3O5S2469.5IKKeCayman862812-98-4InChI=1S/C22H19N3O5S2/c1-28-17-8-15-16(9-18(17)29-2)25(13-24-15)22-10-19(20(11-23)31-22)30-12-14-6-4-5-7-21(14)32(3,26)27/h4-10,13H,12H2,1-3H3LDTAHRLHGHFHKP-UHFFFAOYSA-N11626927CS(C1=C(COC2=C(C#N)SC(N3C=NC4=CC(OC)=C(OC)C=C43)=C2)C=CC=C1)(=O)=O
279CCT250862NEK
327CelastrolC29H38O4450.6hsp90, ampkKim JH. Cell Signal. (2013) 805-13WO2007117466Cayman Chemical34157-83-0InChI=1S/C29H38O4/c1-17-18-7-8-21-27(4,19(18)15-20(30)23(17)31)12-14-29(6)22-16-26(3,24(32)33)10-9-25(22,2)11-13-28(21,29)5/h7-8,15,22,31H,9-14,16H2,1-6H3,(H,32,33)/t22-,25-,26?,27+,28-,29+/m1/s1KQJSQWZMSAGSHN-KUDKLYNCSA-N92310323O=C1C=C2C(=CC=C3[C@@]2(C)CCC2(C)[C@@H]4C[C@@](C)(CC[C@]4(C)CC[C@]32C)C(=O)O)C(=C1O)C
28CGP-57380C11H9FN6244.23MNKKnauf U. (2001) Mol. Cell. Biol. 21 5500-5511Proud C.G. (2005) Immunity 23 177-189WO2010055072Tocris522629-08-9InChI=1S/C11H9FN6/c12-6-1-3-7(4-2-6)16-11-8-9(13)14-5-15-10(8)17-18-11/h1-5H,(H4,13,14,15,16,17,18)UQPMANVRZYYQMD-UHFFFAOYSA-N11644425C1=CC(=CC=C1NC2=C3C(=NC=NC3=NN2)N)F
29CGP-57380 analog (SHN-093)C12H11FN6258.25MNK Proud C.G. (2005) Immunity 23 177-189InChI=1S/C12H11FN6/c1-19-12-9(10(14)15-6-16-12)11(18-19)17-8-4-2-7(13)3-5-8/h2-6H,1H3,(H,17,18)(H2,14,15,16)SIHUJKCSGBNJEM-UHFFFAOYSA-NCn1c2c(c(ncn2)N)c(n1)Nc3ccc(cc3)F
30CGP-57380 analog (SHN-095)C13H14N6254.29MNK InChI=1S/C13H14N6/c1-8-4-3-5-9(6-8)17-12-10-11(14)15-7-16-13(10)19(2)18-12/h3-7H,1-2H3,(H,17,18)(H2,14,15,16)QLLSZPWRBXJUTI-UHFFFAOYSA-NCc1cccc(c1)Nc2c3c(ncnc3n(n2)C)N
31Chelerythrine ChlorideC21H18NO4Cl383.8PKCKandasamy R.A. (1995) J. Biol. Chem. 270 29209Jarvis W.D. (1994) Cancer Res. 54 1707WO2003077917Merck (Calbiochem)3895-92-9InChI=1S/C21H18NO4.ClH/c1-22-10-16-13(6-7-17(23-2)21(16)24-3)14-5-4-12-8-18-19(26-11-25-18)9-15(12)20(14)22;/h4-10H,11H2,1-3H3;1H/q+1;/p-1WEEFNMFMNMASJY-UHFFFAOYSA-M72311C[N+]1=C2C(=C3C=CC(=C(C3=C1)OC)OC)C=CC4=CC5=C(C=C42)OCO5.[Cl-]
33CHIR 99021 (CT 99021)C22H18Cl2N8465.34GSK3Ring D.B. (2003) Diabetes 52 588WO1999065897Axon252917-06-9InChI=1S/C22H18Cl2N8/c1-13-10-29-21(31-13)17-12-30-22(32-20(17)16-4-3-15(23)8-18(16)24)27-7-6-26-19-5-2-14(9-25)11-28-19/h2-5,8,10-12H,6-7H2,1H3,(H,26,28)(H,29,31)(H,27,30,32)AQGNHMOJWBZFQQ-UHFFFAOYSA-N9956119CC1=CN=C(N1)C2=CN=C(N=C2C3=C(C=C(C=C3)Cl)Cl)NCCNC4=NC=C(C=C4)C#N
301ChloroquineC18H26ClN3319.87214Anti Malarial54-05-7InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)WHTVZRBIWZFKQO-UHFFFAOYSA-N2719CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl
34CKI-7C11H12ClN3O2S • 2HCl358.67CK1Rena G. (2004) EMBO Rep. 5 60-65WO2002102768Sigma1177141- 67-1InChI=1S/C11H12ClN3O2S/c12-10-1-2-11(18(16,17)15-6-4-13)9-7-14-5-3-8(9)10/h1-3,5,7,15H,4,6,13H2OGKYMFFYOWUTKV-UHFFFAOYSA-N129236C1=CC(=C2C=CN=CC2=C1S(=O)(=O)NCCN)Cl
35Compound C (Dorsomorphin)C24H25N5O399.5AMPKYu P.B. (2008) Nat. Chem. Biol. 4 33Kim E.K. (2004) J. Biol. Chem. 279 19970WO2008033408A2Merck (Calbiochem)1219168-18-9InChI=1S/C24H25N5O/c1-2-12-28(13-3-1)14-15-30-22-6-4-19(5-7-22)21-16-26-24-23(17-27-29(24)18-21)20-8-10-25-11-9-20/h4-11,16-18H,1-3,12-15H2XHBVYDAKJHETMP-UHFFFAOYSA-N11524144C1CCN(CC1)CCOC2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC=C5)N=C3
166Cot-Tpl2 Inhibitor Compound 10b (Abbott)C20H15N3OS345.42Cot-Tpl2Cusack K. (2009) Bioorganic and MedicinalChemistry Letters 19 1722-1725
138Cot-Tpl2 Inhibitor Compound 38 (Abbott)C21H12F3N5OS439.41Cot-Tpl2George D. Friedman M. (2008) Bioorganic and Medicinal Chemistry Letters 18 4952-4955
135Cot-Tpl2 Inhibitor Compound 41 (Abbott)C21H14N6O2S414.44Cot-Tpl2George D. Friedman M. (2008) Bioorganic and Medicinal Chemistry Letters 18 4952-4955InChI=1S/C21H14N6O2S/c22-20(28)14-3-1-12(2-4-14)13-5-7-15(8-6-13)29-17-10-23-11-19-16(17)9-18(30-19)21-24-26-27-25-21/h1-11H,(H2,22,28)(H,24,25,26,27)NCPSMBVBKJXJPP-UHFFFAOYSA-NCopyC1=CC(=CC=C1C2=CC=C(C=C2)OC3=CN=CC4=C3C=C(S4)C5=NNN=N5)C(=O)N
204CP-690550 (Tasocitinib)C16H20N6O312.38JAKManshouri T. (2008) Cancer Sci. 99(6) 1265-73Selleck477600-75-2InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1UJLAWZDWDVHWOW-YPMHNXCESA-N9926791CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N
341CrenolanibC26H29N5O2443.5FLT3Smith CC (2014 )Proc Natl Acad Sci U S A Apr 8 111(14) 5319-24670220-88-9InChI=1S/C26H29N5O2/c1-26(14-32-15-26)16-33-20-6-7-22-21(13-20)28-17-31(22)24-8-5-18-3-2-4-23(25(18)29-24)30-11-9-19(27)10-12-30/h2-8,13,17,19H,9-12,14-16,27H2,1H3DYNHJHQFHQTFTP-UHFFFAOYSA-N10366136CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4
41CurcuminC21H20O6368.4Inhibits EGF receptorCui L. (2007) Antimicrob. Agents Chemother. 51 488Salvioli S. (2007) eCAM 4 181WO2000070949Merck (Calbiochem)458-37-7InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+VFLDPWHFBUODDF-FCXRPNKRSA-N969516COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O
222CZC-25146C22H25FN6O4S488.54LRRK2Ramsden N. (2011) ASC Chemical Biology InChI=1S/C23H28N6O4S/c1-16-15-24-23(27-22(16)25-18-6-4-5-7-19(18)28-34(3,30)31)26-20-9-8-17(14-21(20)32-2)29-10-12-33-13-11-29/h4-9,14-15,28H,10-13H2,1-3H3,(H2,24,25,26,27)LPNYSGPEOBYEDW-UHFFFAOYSA-NCc1cnc(nc1Nc2ccccc2NS(=O)(=O)C)Nc3ccc(cc3OC)N4CCOCC4
42D 4476C23H18N4O3398.41CK1Liverton N.J. (1999) J. Med. Chem 42 2180-2190WO2008066626Merck (Calbiochem)301836-43-1InChI=1S/C23H18N4O3/c24-22(28)14-4-6-15(7-5-14)23-26-20(21(27-23)17-3-1-2-10-25-17)16-8-9-18-19(13-16)30-12-11-29-18/h1-10,13H,11-12H2,(H2,24,28)(H,26,27)DPDZHVCKYBCJHW-UHFFFAOYSA-N6419753C1COC2=C(O1)C=CC(=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5
328DasatinibC22H26ClN7O2S487BCR-ABL, SrcKantarjian H. N Engl J Med. (2010) 2260-70WO2009094556Cayman Chemical302962-49-8InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27) ZBNZXTGUTAYRHI-UHFFFAOYSA-N3062316CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCOCopy
283Dimethyl fumarateC6H8O4144.13Peng H. (2112) J Biol Chem. 287(33) 28017-26Gesser B. (2007) Journal of Investigative Dermatology 27(9) 2129-37Sigma624-49-7InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+LDCRTTXIJACKKU-ONEGZZNKSA-N637568COC(=O)C=CC(=O)OC
43EGCG (Epigallocatechin Gallate)C22H18O11458.4PKCDell'Aica I. (2004) EMBO Rep. 5 418-422Tachibana H. (2004) Nat. Struct. Mol. Biol. 11 380WO2001051048Merck (Calbiochem)989-51-5InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1WMBWREPUVVBILR-WIYYLYMNSA-N65064C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)
350EMD638683C18H18F2N364.34SGK1Miyayama T (2014) Environ Toxicol Pharmacol 38(2) 374-8US20110600501181770-72-8InChI=1S/C18H18F2N2O4/c1-3-13-9(2)15(23)5-4-14(13)17(25)21-22-18(26)16(24)10-6-11(19)8-12(20)7-10/h4-8,16,23-24H,3H2,1-2H3,(H,21,25)(H,22,26)SSNAPUUWBPZGOY-UHFFFAOYSA-N44182398CCC1=C(C=CC(=C1C)O)C(=O)NNC(=O)C(C2=CC(=CC(=C2)F)F)O
143ER-27319C20H22N2O5370.40SYKMoriya K. (1997) Proc. Natl. Acad. Sci. USA 94 12539-12544Tocris201010-95-9InChI=1S/C18H20N2O.C2H2O4/c1-12-8-9-15-17(13(12)2)20(11-5-10-19)16-7-4-3-6-14(16)18(15)21;3-1(4)2(5)6/h3-4,6-9H,5,10-11,19H2,1-2H3;(H,3,4)(H,5,6)IIELZHYJYZBSGG-UHFFFAOYSA-N9799508CC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3N2CCCN)C.C(=O)(C(=O)O)O
220ETP 46464C30H22N4O2470.52ATRiToledo L.I. (2011) Nature structural and molecular biology 18 721-727InChI=1S/C30H22N4O2/c1-30(2,18-31)23-8-10-24(11-9-23)34-28-22(17-36-29(34)35)16-33-27-12-7-19(14-25(27)28)21-13-20-5-3-4-6-26(20)32-15-21/h3-16H,17H2,1-2H3DPLMXAYKJZOTKO-UHFFFAOYSA-NCC(C)(C#N)c1ccc(cc1)N2c3c4cc(ccc4ncc3COC2=O)c5cc6ccccc6nc5
200Febuxostat (TMX-67, Adenuric, Uloric)C16H16N2O3S316.37Xanthine oxidase (XO)Gaffo AL. (2010 ) Core Evid. 4 25-36Grabowski B (2010) Br J Clin Pharmacol. 70 57-64Selleck144060-53-7InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)BQSJTQLCZDPROO-UHFFFAOYSA-N134018CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O
44FMK (Caspase Inhibitor I)C22H30FN3O7467.5CaspaseMartin U. (2007) Apoptosis 12 525Misaghi S. (2004) Chem. Biol. 11 1677WO2001058526Merck (Calbiochem)187389-52-2InChI=1S/C22H30FN3O7/c1-13(2)19(26-22(31)33-12-15-8-6-5-7-9-15)21(30)24-14(3)20(29)25-16(17(27)11-23)10-18(28)32-4/h5-9,13-14,16,19H,10-12H2,1-4H3,(H,24,30)(H,25,29)(H,26,31)MIFGOLAMNLSLGH-UHFFFAOYSA-N5737CC(C)C(C(=O)NC(C)C(=O)NC(CC(=O)OC)C(=O)CF)NC(=O)OCC1=CC=CC=C1
314FostamatinibC23H26FN6O9P580.46SeleckInChI=1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)GKDRMWXFWHEQQT-UHFFFAOYSA-N11671467CC1(C(=O)N(c2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)COP(=O)(O)O)C
45GDC-0941C23H29N7O3S2Cl2586.57PI3KFolkes AJ. (2008) J Med Chem. 5522-32WO2007129161Axon957054-30-7InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)LHNIIDJUOCFXAP-UHFFFAOYSA-N17755052CS(=O)(=O)N1CCN(CC1)CC2=CC3=C(S2)C(=NC(=N3)C4=C5C=NNC5=CC=C4)N6CCOCC6
290Genentech LRRK2 inhibitor compound 18 (GNE-7915)C19H21F4N5O3443.40LRRK2Estrada AA (2012) J Med Chem 55(22) 9416-33
291Genentech LRRK2 inhibitor compound 19C20H21F4N5O3455.41LRRK2Estrada AA (2012) J Med Chem 55(22) 9416-33
46GenisteinC15H10O5270.2Tyrosine-kinasesConstantinou A. and Huberman E. (1995) Proc. Soc. Exp. Biol. Med. 208 109Wei H. (1995) Proc. Soc. Exp. Biol. Med. 208 124WO1999045920Merck (Calbiochem)446-72-0InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18HTZBJGXHYKVUXJN-UHFFFAOYSA-N5280961C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O
47GF 109203X (Go 6850)C25H24N4O2412.5PKCHers I. (1999) FEBS Lett. 460 433Ku W.-C. (1997) Biochem. Biophys. Res. Commun. 241 730US7067144Merck (Calbiochem)133052-90-1InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6,8-11,14-15,26H,7,12-13H2,1-2H3,(H,27,30,31)QMGUOJYZJKLOLH-UHFFFAOYSA-N2396CN(C)CCCN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54
48Gleevec (Imatinib)C29H31N7O493.6BCR-ABLDruker B. J. (2000) J. Clin. Invest. 105 3-7WO2006039533Tocris152459-95-5InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)KTUFNOKKBVMGRW-UHFFFAOYSA-N5291CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
49Gö 6976C24H18N4O378.4PKCGschwendt M. (1996) FEBS Lett. 392 77Wenzel-Seifert K. (1994) Biochem. Biophys. Res. Commun. 200 1536WO2003009809Merck (Calbiochem)136194-77-9InChI=1S/C24H18N4O/c1-27-17-9-4-2-7-14(17)20-21-16(13-26-24(21)29)19-15-8-3-5-10-18(15)28(12-6-11-25)23(19)22(20)27/h2-5,7-10H,6,12-13H2,1H3,(H,26,29)VWVYILCFSYNJHF-UHFFFAOYSA-N3501CN1C2=CC=CC=C2C3=C4C(=C5C6=CC=CC=C6N(C5=C31)CCC#N)CNC4=O
50Gö 7874C27H26N4O4 • HCl507PKCKleinschroth J. (1995) Bioorg. Med. Chem. Lett. 5 55US20080153903Merck (Calbiochem)287935-76-6InChI=1S/C27H26N4O4/c1-29(2)12-14(32)13-31-19-8-6-5-7-16(19)20-22-23(27(34)28-26(22)33)21-17-11-15(35-4)9-10-18(17)30(3)24(21)25(20)31/h5-11,14,32H,12-13H2,1-4H3,(H,28,33,34)XIKQYZCJVULUHD-UHFFFAOYSA-N5327863CN1C2=C(C=C(C=C2)OC)C3=C4C(=C5C6=CC=CC=C6N(C5=C31)CC(CN(C)C)O)C(=O)NC4=O
158GSK2334470C25H34N8O462.59PDK1Najafov A. (2011) Biochem. J. 433 357-69Tocris1227911-45-6InChI=1S/C25H34N8O/c1-15-8-9-17(24(34)28-18-6-4-3-5-7-18)14-33(15)22-13-20(29-25(27-2)30-22)16-10-11-19-21(12-16)31-32-23(19)26/h10-13,15,17-18H,3-9,14H2,1-2H3,(H,28,34)(H3,26,31,32)(H,27,29,30)/t15-,17+/m1/s1QLPHOXTXAKOFMU-WBVHZDCISA-N46215815CC1CCC(CN1C2=NC(=NC(=C2)C3=CC4=C(C=C3)C(=NN4)N)NC)C(=O)NC5CCCCC5
260GSK2578215AC24H18FN3O2399.42LRRK2Reith A. (2012) Bioorg. Med. Chem. Lett.WO2011038572
317GSK2606414C24H20F3N5O451.44PERKAxten JM. (2012) J. Med. Chem. 23 55(16) 7193-207Merck MilliporeInChI=1S/C24H20F3N5O/c1-31-12-18(21-22(28)29-13-30-23(21)31)15-5-6-19-16(11-15)7-8-32(19)20(33)10-14-3-2-4-17(9-14)24(25,26)27/h2-6,9,11-13H,7-8,10H2,1H3,(H2,28,29,30)SIXVRXARNAVBTC-UHFFFAOYSA-N53469448CN1C=C(C2=C1N=CN=C2N)C3=CC4=C(C=C3)N(CC4)C(=O)CC5=CC(=CC=C5)C(F)(F)F
153GSK269962AC29H30N8O5570.61ROCKDoe C. (2007) J Pharmacol Exp Ther 320 89-98Axon850664-21-0InChI=1S/C29H30N8O5/c1-2-37-24-17-25(31-18-23(24)33-28(37)26-27(30)35-42-34-26)41-22-5-3-4-20(16-22)32-29(38)19-6-8-21(9-7-19)40-15-12-36-10-13-39-14-11-36/h3-9,16-18H,2,10-15H2,1H3,(H2,30,35)(H,32,38)YOVNFNXUCOWYSG-UHFFFAOYSA-N16095342CCN1C2=CC(=NC=C2N=C1C3=NON=C3N)OC4=CC=CC(=C4)NC(=O)C5=CC=C(C=C5)
152GSK429286C21H16F4N4O2432.37ROCKGoodman K. (2007) J. Med. Chem. 50 (1), 6-9Nichols (2009) Biochem.J. 424 47Tocris864082-47-3InChI=1S/C21H16F4N4O2/c1-10-19(20(31)28-17-6-12-9-26-29-16(12)8-15(17)22)14(7-18(30)27-10)11-2-4-13(5-3-11)21(23,24)25/h2-6,8-9,14H,7H2,1H3,(H,26,29)(H,27,30)(H,28,31)OLIIUAHHAZEXEX-UHFFFAOYSA-N11373846CC1=C(C(CC(=O)N1)C2=CC=C(C=C2)C(F)(F)F)C(=O)NC3=C(C=C4C(=C3)C=NN4)F
250GSK461364C27H28F3N5O2S543.6PLK1T. R. Rheault (2010) Bioorg. Med. Chem. Lett. 20(15) 4587-92K. A. Emmitte (2009) Bioorg. Med. Chem. Lett. 19(6) 1694-7Axon929095-18-1InChI=1S/C27H28F3N5O2S/c1-17(19-5-3-4-6-20(19)27(28,29)30)37-23-14-24(38-25(23)26(31)36)35-16-32-21-8-7-18(13-22(21)35)15-34-11-9-33(2)10-12-34/h3-8,13-14,16-17H,9-12,15H2,1-2H3,(H2,31,36)/t17-/m1/s1ZHJGWYRLJUCMRT-QGZVFWFLSA-N15983966CC(C1=CC=CC=C1C(F)(F)F)OC2=C(SC(=C2)N3C=NC4=C3C=C(C=C4)CN5CCN(CC5)C)C(=O)N
146GSK650394AC25H22N2O2382.45SGKSherk A. B. (2008) Cancer Res 68 7475–7483Tocris890842-28-1InChI=1S/C25H22N2O2/c28-25(29)20-11-10-18(12-21(20)17-8-4-5-9-17)23-15-27-24-22(23)13-19(14-26-24)16-6-2-1-3-7-16/h1-3,6-7,10-15,17H,4-5,8-9H2,(H,26,27)(H,28,29)WVSBGSNVCDAMCF-UHFFFAOYSA-N25022668C1CCC(C1)C2=C(C=CC(=C2)C3=CNC4=NC=C(C=C34)C5=CC=CC=C5)C(=O)O
207GW441756 hydrochlorideC17H13N3O • HCl311.77Trk AWood E.R. (2004) Bioorg. Med. Chem. Lett. 14 953-957Sigma504433-24-3InChI=1S/C17H13N3O.ClH/c1-20-10-11(12-5-2-3-7-15(12)20)9-13-16-14(19-17(13)21)6-4-8-18-16;/h2-10H,1H3,(H,19,21);1HGXUJPQDCLCDKLU-UHFFFAOYSA-N16219400CN1C=C(C2=CC=CC=C21)C=C3C4=C(C=CC=N4)NC3=O.Cl
137GW501516C21H18F3NO3S2 453.5PPARdSznaidman M.L. (2003) Bioorg Med Chem Lett 13(9) 1517-21Enzo (Alexis)317318-70-0InChI=1S/C21H18F3NO3S2/c1-12-9-16(7-8-17(12)28-10-19(26)27)29-11-18-13(2)25-20(30-18)14-3-5-15(6-4-14)21(22,23)24/h3-9H,10-11H2,1-2H3,(H,26,27)YDBLKRPLXZNVNB-UHFFFAOYSA-N9803963CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=CC=C(C=C3)C(F)(F)F)C)OCC(=O)O
52GW5074 (Raf1 Kinase Inhibitor I)C15H8Br2INO2520.9cRAF1Lackey K. (2000) Bioorg. Med. Chem. Lett. 10 223WO2010036813Merck (Calbiochem)220904-83-6InChI=1S/C15H8Br2INO2/c16-11-4-7(5-12(17)14(11)20)3-10-9-6-8(18)1-2-13(9)19-15(10)21/h1-6,20H,(H,19,21)/b10-3-LMXYVLFTZRPNRV-KMKOMSMNSA-N5924208C1=CC2=C(C=C1I)C(=CC3=CC(=C(C(=C3)Br)O)Br)C(=O)N2
217GW843682X (GSK-PLK1 Compound 2)C22H18F3N3O4S477.46PLK1Emmitte K.A. (2009) Bioorganic and Medicinal Chemistry Letters 19 1018-1021Tocris660868-91-7InChI=1S/C22H18F3N3O4S/c1-30-16-7-14-15(8-17(16)31-2)28(11-27-14)19-9-18(20(33-19)21(26)29)32-10-12-5-3-4-6-13(12)22(23,24)25/h3-9,11H,10H2,1-2H3,(H2,26,29)JSKUWFIZUALZLX-UHFFFAOYSA-N9826308COC1=C(C=C2C(=C1)N=CN2C3=CC(=C(S3)C(=O)N)OCC4=CC=CC=C4C(F)(F)F)OC
53H-1152 (Rho Kinase Inhibitor)C16H21N3O2S • 2HCl392.3ROCKIkenoya M. (2002) J. Neurochem. 81 9Sasaki Y. (2002) Pharmacol. Ther. 93 225WO2010010702Merck (Calbiochem)451462-58-1InChI=1S/C16H21N3O2S.2ClH/c1-12-9-18-11-14-5-3-6-15(16(12)14)22(20,21)19-8-4-7-17-10-13(19)2;;/h3,5-6,9,11,13,17H,4,7-8,10H2,1-2H3;2*1H/t13-;;/m1../s1BFOPDSJOLUQULZ-FFXKMJQXSA-N16760633CC1CNCCCN1S(=O)(=O)C2=CC=CC3=CN=CC(=C32)C.Cl.Cl
54H-7, DihydrochlorideC14H17N3O2S • 2HCl364.3serine/threonine kinasesKu W.C. (1997) Biochem. Biophys. Res. Commun. 241 730Jarvis W.D. (1994) Cancer Res. 54 1707WO1999041984Merck (Calbiochem)84477-87-2InChI=1S/C14H17N3O2S/c1-11-9-16-7-8-17(11)20(18,19)14-4-2-3-12-10-15-6-5-13(12)14/h2-6,10-11,16H,7-9H2,1H3BDVFVCGFMNCYPV-UHFFFAOYSA-N3542CC1CNCCN1S(=O)(=O)C2=CC=CC3=C2C=CN=C3
55H-8, DihydrochlorideC12H15N3O2S • 2HCl338.3serine/threonine kinasesIdo M. (1991) Br. J. Cancer 64 1103Hagiwara M. (1987) Mol. Pharmacol. 31 523WO1999041984Merck (Calbiochem)113276-94-1InChI=1S/C12H15N3O2S/c1-13-7-8-15-18(16,17)12-4-2-3-10-9-14-6-5-11(10)12/h2-6,9,13,15H,7-8H2,1H3/p+1PJWUXKNZVMEPPH-UHFFFAOYSA-O7000066C[NH2+]CCNS(=O)(=O)C1=CC=CC2=C1C=CN=C2
56H-89, DihydrochlorideC20H20BrN3O2S • 2HCl519.3PKALeemhuis J. (2002) J. Pharmacol. Exp. Ther. 300 1000Davies S.P. (2000) Biochem. J. 351 95WO2003080649Merck (Calbiochem)127243-85-0InChI=1S/C20H20BrN3O2S.2ClH/c21-18-8-6-16(7-9-18)3-2-11-22-13-14-24-27(25,26)20-5-1-4-17-15-23-12-10-19(17)20;;/h1-10,12,15,22,24H,11,13-14H2;2*1H/b3-2+;;GELOGQJVGPIKAM-WTVBWJGASA-N5702541C1=CC2=C(C=CN=C2)C(=C1)S(=O)(=O)NCCNCC=CC3=CC=C(C=C3)Br.Cl.Cl
57HA-1077, Dihydrochloride (Fasudil)C14H17N3O2S • 2HCl364.3PKAWatanabe K. (2007) Nature Biotechnology 25 681Swärd K. (2000) J. Physiol. 522 33WO1999041984Merck (Calbiochem)103745-39-7InChI=1S/C14H17N3O2S.2ClH/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14;;/h1,3-5,7,11,15H,2,6,8-10H2;2*1HNOXXIYDYFSNHDF-UHFFFAOYSA-N16219471C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CN=C3.Cl.Cl
147HA-1100 (Hydroxyfasudil)C14H17N3O3S.HCl343.83ROCKS. Wolfrum (2004) Arterioscler. Thromb. Vasc. Biol. 24 1842Merck (Calbiochem)105628-72-6InChI=1S/C14H17N3O3S/c18-14-12-3-1-4-13(11(12)5-7-16-14)21(19,20)17-9-2-6-15-8-10-17/h1,3-5,7,15H,2,6,8-10H2,(H,16,18)ZAVGJDAFCZAWSZ-UHFFFAOYSA-N3064778C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CNC3=O
58HarmalineC13H14N2O214.263serotonin, monoamine oxidaseHerraiz T. (2013) Drug Test. 1002/dta.1530.WO1999041984Sigma304-21-2InChI=1S/C13H14N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-4,7,14H,5-6H2,1-2H3QJOZJXNKVMFAET-UHFFFAOYSA-N5280951CC1=C2C(=C3C=CC(=CC3=N2)OC)CCN1
59HarmalolC12H12N2O • HCl • 2H2O272.73serotonin, monoamine oxidaseRiba J. (2012) Drug Test. 610-6.US5256533Sigma6028-00-8InChI=1S/C12H12N2O/c1-7-12-10(4-5-13-7)9-3-2-8(15)6-11(9)14-12/h2-3,6,13-14H,4-5H2,1H3CRQDWQWZCNKKAC-UHFFFAOYSA-N5353656CC1=C2C(=C3C=CC(=O)C=C3N2)CCN1
60HarmaneC12H10N2182.22serotonin, monoamine oxidaseSmith KL. (2013) J Psychopharmacol. 162-70US5256533Sigma486-84-0InChI=1S/C12H10N2/c1-8-12-10(6-7-13-8)9-4-2-3-5-11(9)14-12/h2-7,14H,1H3PSFDQSOCUJVVGF-UHFFFAOYSA-N5281404CC1=NC=CC2=C1NC3=CC=CC=C23
61HarmineC13H12N2O212.25serotonin, monoamine oxidaseSong Y. (2004) Biochem. Biophys. Res. Commun. 317 128–132US5256533Sigma442-51-3InChI=1S/C13H12N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-7,15H,1-2H3BXNJHAXVSOCGBA-UHFFFAOYSA-N5280953CC1=NC=CC2=C1NC3=C2C=CC(=C3)OC
261HG-10-102-01LRRK2Choi H.G. (2012) ACS Med. Chem. Lett.
286HG-9-91-01C32H38ClN7O3604.14SIKClark K. (2012) Proc Natl Acad Sci USA 109(42) 16986-91
254HypothemycinC19H22O8378.37cyclin D1H. Sonoda (1999) Life Sci. 65 381A. Zhao (1999) J. Antibiot. 52 1086Sigma76958-67-3InChI=1S/C19H22O8/c1-9-4-3-5-12(20)18-15(27-18)8-14(22)17(23)11-6-10(25-2)7-13(21)16(11)19(24)26-9/h3,5-7,9,14-15,17-18,21-23H,4,8H2,1-2H3/b5-3-/t9?,14?,15?,17-,18?/m0/s1HDZUUVQEDFZKAX-JOLUUEAESA-N6474405CC1CC=CC(=O)C2C(O2)CC(C(C3=CC(=CC(=C3C(=O)O1)O)OC)O)O
62IC261C18H17NO4311.3CK1Behrend L. (2000) Oncogene 19 5303Mashhoon N. (2000) J. Biol. Chem. 275 20052WO2008066626Merck (Calbiochem)186611-52-9InChI=1S/C18H17NO4/c1-21-11-8-16(22-2)14(17(9-11)23-3)10-13-12-6-4-5-7-15(12)19-18(13)20/h4-10H,1-3H3,(H,19,20)/b13-10+JBJYTZXCZDNOJW-JLHYYAGUSA-N5288600COC1=CC(=C(C(=C1)OC)C=C2C3=CC=CC=C3NC2=O)OC
172IKK Inhibitor VIIC28H29N5OS 483.6 IKKWaelchli R. (2006) Bioorg. Med. Chem. Lett. 16 108Merck (Calbiochem)873225-46-8InChI=1S/C28H29N5OS/c34-27(33-17-12-23(13-18-33)32-15-3-4-16-32)20-7-9-22(10-8-20)30-28-29-14-11-24(31-28)26-19-21-5-1-2-6-25(21)35-26/h1-2,5-11,14,19,23H,3-4,12-13,15-18H2,(H,29,30,31)BWZJBXAPRCVCKQ-UHFFFAOYSA-N9549298C1CCN(C1)C2CCN(CC2)C(=O)C3=CC=C(C=C3)NC4=NC=CC(=N4)C5=CC6=CC=CC=C6S5
63IKK-2 Inhibitor IV (TPCA-1)C12H10FN3O2S279.3IKK2Podolin P.L. (2005) J. Pharmacol. Exp. Ther. 312 373Karin M. (2004) Nat. Rev. Drug Discov. 3 17WO2008144011Merck (Calbiochem)507475-17-4InChI=1S/C12H10FN3O2S/c13-7-3-1-6(2-4-7)9-5-8(10(14)17)11(19-9)16-12(15)18/h1-5H,(H2,14,17)(H3,15,16,18)SAYGKHKXGCPTLX-UHFFFAOYSA-N9903786C1=CC(=CC=C1C2=CC(=C(S2)NC(=O)N)C(=O)N)F
173IKK-2 Inhibitor VIIIC21H24N4O2364.4 IKK2Murata T. (2004) Bioorg. Med. Chem. Lett. 14 4019 Merck (Calbiochem)406208-42-2InChI=1S/C21H24N4O2.ClH/c22-11-16-15(14-6-8-24-9-7-14)10-17(25-21(16)23)20-18(26)2-1-3-19(20)27-12-13-4-5-13;/h1-3,10,13-14,24-25H,4-9,12,23H2;1H/b20-17-;BKIZYSPLJNGJEL-BZHDPTRRSA-N66576999C1CC1COC2=CC=CC(=O)C2=C3C=C(C(=C(N3)N)C#N)C4CCNCC4.Cl
64IKK-3 inhibitor IXC22H19N3O5S2469.5IKK3Bamborough P. (2006) Bioorg. Med. Chem. Lett. 16 6236US20120134931Merck (Calbiochem)862812-98-4InChI=1S/C22H19N3O5S2/c1-28-17-8-15-16(9-18(17)29-2)25(13-24-15)22-10-19(20(11-23)31-22)30-12-14-6-4-5-7-21(14)32(3,26)27/h4-10,13H,12H2,1-3H3LDTAHRLHGHFHKP-UHFFFAOYSA-N11626927COC1=C(C=C2C(=C1)N=CN2C3=CC(=C(S3)C#N)OCC4=CC=CC=C4S(=O)(=O)C)OC
167IMD-0354C15H8ClF6NO2383.67IKK2Tanaka A, (2005) Blood 105 2324-2331Sigma978-62-1InChI=1S/C15H8ClF6NO2/c16-9-1-2-12(24)11(6-9)13(25)23-10-4-7(14(17,18)19)3-8(5-10)15(20,21)22/h1-6,24H,(H,23,25)CHILCFMQWMQVAL-UHFFFAOYSA-N5081913C1=CC(=C(C=C1Cl)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)O
133IPA-3C20H14O2S2350.45PAK1Deacon S.W. (2008) Chemistry and Biology 15 322Merck (Calbiochem)42521-82-4InChI=1S/C20H14O2S2/c21-17-11-9-13-5-1-3-7-15(13)19(17)23-24-20-16-8-4-2-6-14(16)10-12-18(20)22/h1-12,21-22HRFAXLXKIAKIUDT-UHFFFAOYSA-N521106C1=CC=C2C(=C1)C=CC(=C2SSC3=C(C=CC4=CC=CC=C43)O)O
145IRAK 1-4 Inhibitor 1C20H21N5O4395.41IRAK1, IRAK4Powers J. P. (2006) Bioorg. Med. Chem. Lett. 16 2842-2845Merck (Calbiochem)509093-47-4InChI=1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26)QTCFYQHZJIIHBS-UHFFFAOYSA-N11983295C1COCCN1CCN2C3=CC=CC=C3N=C2NC(=O)C4=CC(=CC=C4)[N+](=O)[O-]
65IRAK-4 kinase inhibitor aC22H24N4O6440.45IRAK4Wang Z. (2006) Structure 14 1835-1844InChI=1S/C22H26N4O6/c1-22(2,3)20(29)32-16-8-9-18-17(13-16)23-21(25(18)10-5-11-27)24-19(28)14-6-4-7-15(12-14)26(30)31/h4,6-9,12-13,27,30-31H,5,10-11H2,1-3H3,(H,23,24,28)RKAASBGJMVRFNL-UHFFFAOYSA-NCC(C)(C)C(=O)Oc1ccc2c(c1)nc(n2CCCO)NC(=O)c3cccc(c3)N(O)O
258IRAK-4 kinase inhibitor bC22H24N4O6440.45IRAK4
221IscheminC15H17N3O4S335.38p53 CBPJagat C. Borah (2011) Chemistry & Biology, 18 4 531-541
252JNKIN7C28H27N7O2493.56JNKZhang T. (2012) Chem Biol. 19(1) 140-54
253JNKIN8C29H29N7O2507.59JNKZhang T. (2012) Chem Biol. 19(1) 140-54
66K252aC27H21N3O5467.5CaMKIICools J. (2004) Cancer Res. 64 6385Chin L.S. (1999) Cancer Invest. 17 391WO2011114220Merck (Calbiochem)99533-80-9InChI=1S/C27H21N3O5/c1-26-27(33,25(32)34-2)11-18(35-26)29-16-9-5-3-7-13(16)20-21-15(12-28-24(21)31)19-14-8-4-6-10-17(14)30(26)23(19)22(20)29/h3-10,18,33H,11-12H2,1-2H3,(H,28,31)/t18-,26+,27?/m1/s1KOZFSFOOLUUIGY-UHOLRESSSA-N127357CC12C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(C(=O)OC)O
292Kalopanaxsaponin AC41H66O12750.96104748-88-1InChI=1S/C41H66O12/c1-21-28(44)30(46)31(47)33(51-21)53-32-29(45)24(43)19-50-34(32)52-27-11-12-37(4)25(38(27,5)20-42)10-13-40(7)26(37)9-8-22-23-18-36(2,3)14-16-41(23,35(48)49)17-15-39(22,40)6/h8,21,23-34,42-47H,9-20H2,1-7H3,(H,48,49)/t21-,23-,24-,25+,26+,27-,28-,29-,30+,31+,32+,33-,34-,37-,38-,39+, 40+,41-/m0/s1KEOITPILCOILGM-LLJOFIFVSA-N73296CC1C(C(C(C(O1)OC2C(C(COC2OC3CCC4(C(C3(C)CO)CCC5(C4CC=C6C5(CCC7(C6CC(CC7)(C)C)C(=O)O)C)C)C)O)O)O)O)O
67KenpaulloneC16H11BrN2O327.2GSK, CDKBain J. (2003) Biochem. J. 371 199Buolamwini J.K. (2000) Curr. Pharm. Des. 6 379WO2013184591Merck (Calbiochem)142273-20-9InChI=1S/C16H11BrN2O/c17-9-5-6-14-11(7-9)12-8-15(20)18-13-4-2-1-3-10(13)16(12)19-14/h1-7,19H,8H2,(H,18,20)QQUXFYAWXPMDOE-UHFFFAOYSA-N3820C1C2=C(C3=CC=CC=C3NC1=O)NC4=C2C=C(C=C4)Br
226KIN 112C32H36N6O4568.67LckMartin M.W. (2006) J.Med.Chem. 49 4981-4991
69KN62C38H35N5O6S2721.9CaMKIIMinami H. (1994) Biochem. Biophys. Res. Commun. 199 241US20080255244Merck (Calbiochem)127191-97-3InChI=1S/C38H35N5O6S2/c1-41(50(45,46)36-11-5-7-29-26-39-19-17-33(29)36)35(38(44)43-23-21-42(22-24-43)31-9- 3-2-4-10-31)25-28-13-15-32(16-14-28)49-51(47,48)37-12-6-8-30-27-40-20-18-34(30)37/h2-20,26-27,35H,21-25H2,1H3/t35-/m0/s1RJVLFQBBRSMWHX-DHUJRADRSA-N5312126CN(C(CC1=CC=C(C=C1)OS(=O)(=O)C2=CC=CC3=C2C=CN=C3)C(=O)N4CCN(CC4)C5=CC=CC=C5)S(=O)(=O)C6=CC=CC7=C6C=CN=C7
70KN93C26H29CIN2O4S501CaMKIIFan G.H. (1999) Mol. Pharmacol. 56 39Tombes R.M. (1995) Cell Growth Differ. 6 1063WO2009042906Merck (Calbiochem)139298-40-1InChI=1S/C26H29ClN2O4S/c1-28(17-5-6-21-9-11-23(27)12-10-21)20-22-7-3-4-8-26(22)29(18-19-30)34(31,32)25-15-13-24(33-2)14-16-25/h3-16,30H,17-20H2,1-2H3/b6-5+LLLQTDSSHZREGW-AATRIKPKSA-N5312122CN(CC=CC1=CC=C(C=C1)Cl)CC2=CC=CC=C2N(CCO)S(=O)(=O)C3=CC=C(C=C3)OC
71KT5720C32H31N3O5537.6PKASimpson CS. Morris BJ. (1995) Neuroscience 68 97-106Cabell L. Audesirk G. (1993) Int. J. Dev. Neurosci. 11 357US20100216703Merck (Calbiochem)108068-98-0InChI=1S/C32H31N3O5/c1-3-4-5-10-15-39-30(37)32(38)16-23-34-21-13-8-6-11-18(21)25-26-20(17-33-29(26)36)24-19-12-7-9-14-22(19)35(28(24)27(25)34)31(32,2)40-23/h6-9,11-14,23,38H,3-5,10,15-17H2,1-2H3,(H,33,36)/t23-,31+,32+/m0/s1ZHEHVZXPFVXKEY-RUAOOFDTSA-N454202CCCCCCOC(=O)C1(CC2N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N(C7=C53)C1(O2)C)CNC6=O)O
150KU 0063794C25H31N5O4465.54mTORJuan M. García-Martínez (2009) Biochem J. 421 29–42Tocris938440-64-3InChI=1S/C25H31N5O4/c1-16-13-30(14-17(2)34-16)25-27-23-20(24(28-25)29-8-10-33-11-9-29)5-6-21(26-23)18-4-7-22(32-3)19(12-18)15-31/h4-7,12,16-17,31H,8-11,13-15H2,1-3H3/t16-,17+RFSMUFRPPYDYRD-CALCHBBNSA-N16736978CC1CN(CC(O1)C)C2=NC3=C(C=CC(=N3)C4=CC(=C(C=C4)OC)CO)C(=N2)N5CCOCC5
159KU 55933C21H17NO3S2395.49ATM kinaseHickson (2004) Cancer Res. 64 9152Tocris587871-26-9InChI=1S/C21H17NO3S2/c23-14-12-16(25-20(13-14)22-8-10-24-11-9-22)15-4-3-7-19-21(15)27-18-6-2-1-5-17(18)26-19/h1-7,12-13H,8-11H2XRKYMMUGXMWDAO-UHFFFAOYSA-N5278396C1COCCN1C2=CC(=O)C=C(O2)C3=C4C(=CC=C3)SC5=CC=CC=C5S4
318KU55933C21H17NO3S2395.49ATMLi Y. (2010) Mol. Cancer Ther. 2010 Jan. 9(1) 113-25Tocris Bioscience587871-26-9InChI=1S/C21H17NO3S2/c23-14-12-16(25-20(13-14)22-8-10-24-11-9-22)15-4-3- 7-19-21(15)27-18-6-2-1-5-17(18)26-19/h1-7,12-13H,8-11H2XRKYMMUGXMWDAO-UHFFFAOYSA-N5278396C1COCCN1C2=CC(=O)C=C(O2)C3=C4C(=CC=C3)SC5=CC=CC=C5S4
180LDN-193189C25H22N6406.49BMPYu (2008) Nat. Chem. Biol. 4 33–41Cuny (2008) Bioorg. Med. Chem. Lett. 18 4388–4392Miltenyi Biotech1062368-24-4InChI=1S/C25H22N6/c1-2-4-24-22(3-1)21(9-10-27-24)23-16-29-31-17-19(15-28-25(23)31)18-5-7-20(8-6-18)30-13-11-26-12-14-30/h1-10,15-17,26H,11-14H2CDOVNWNANFFLFJ-UHFFFAOYSA-N25195294C1CN(CCN1)C2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC6=CC=CC=C56)N=C3
298LeflunomideC12H9F3N2O2270.2072775706-12-6InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13, 14)15/h2-6H,1H3,(H,17,18)VHOGYURTWQBHIL-UHFFFAOYSA-N3899CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F
284Lenalidomide (Revlimid)C13H13N3O3259.26TNF-αRushworth S.A. (2013) Cellular Signalling 25 1 106-112Selleck191732-72-6InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)GOTYRUGSSMKFNF-UHFFFAOYSA-N216326C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
203LFM-A13C11H8Br2N2O2360.0BTKVassilev J.Biol.Chem. 274 1646Mahajan et al J.Biol.Chem. 274 9587Tocris62004-35-7InChI=1S/C11H8Br2N2O2/c1-6(16)8(5-14)11(17)15-10-4-7(12)2-3-9(10)13/h2-4,16H,1H3,(H,15,17)/b8-6-UVSVTDVJQAJIFG-VURMDHGXSA-N54676905CC(=C(C#N)C(=O)NC1=C(C=CC(=C1)Br)Br)O
72LiClClLi42.394GSK3bGalli C. (2013) Clin Oral Implants Res. 921-7.WO2001074164Sigma7447-41-8InChI=1S/ClH.Li/h1H;/q;+1/p-1KWGKDLIKAYFUFQ-UHFFFAOYSA-M433294[Li+].[Cl-]
183LRRK2-IN1C31H38N8O3570.69LRRK2Deng X. (2011) Nat. Chem. Biol. 7 203WO2010080712InChI=1S/C31H38N8O3/c1-35-15-17-38(18-16-35)22-11-13-39(14-12-22)29(40)21-9-10-24(27(19-21)42-4)33-31-32-20-26-28(34-31)36(2)25-8-6-5-7-23(25)30(41)37(26)3/h5-10,19-20,22H,11-18H2,1-4H3,(H,32,33,34)IWMCPJZTADUIFX-UHFFFAOYSA-NCN1CCN(CC1)C2CCN(CC2)C(=O)C3=CC(=C(C=C3)NC4=NC=C5C(=N4)N(C6=CC=CC=C6C(=O)N5C)C)OCCopy
73LY294002C19H17NO3307.4PI3KBaumann P. and West S.C. (1998) Proc. Natl. Acad. Sci. USA 95 14066Cardone M.H. (1998) Science 282 1318WO2013097266Promega154447-36-6InChI=1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2CZQHHVNHHHRRDU-UHFFFAOYSA-N3973C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
74LY333531 (Ruboxistaurin)C28H28IN4O3 .CH4O3S582.73PKCJirousek M.R. (1996) J. Med. Chem. 39 2664Tang S. (2008) Proteins 72(1) 447-60WO2000053013Axon192050-59-2InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1ZCBUQCWBWNUWSU-SFHVURJKSA-N153999CN(C)CC1CCN2C=C(C3=CC=CC=C32)C4=C(C5=CN(CCO1)C6=CC=CC=C65)C(=O)NC4=O
184LY364947C17H12N4272.31TGF-β type-ISawyer (2003) J.Med.Chem. 46 3953Li (2006) J.Med.Chem. 49 2138Sigma396129-53-6InChI=1S/C17H12N4/c1-2-6-15-13(5-1)12(8-10-19-15)14-11-20-21-17(14)16-7-3-4-9-18-16/h1-11H,(H,20,21)IBCXZJCWDGCXQT-UHFFFAOYSA-N447966C1=CC=C2C(=C1)C(=CC=N2)C3=C(NN=C3)C4=CC=CC=N4
215Merck 7 (PDK1)C28H22F2N4O4516.5PDK1Nagashima K. (2011) J.Biol.Chem. 286 6433-6448InChI=1S/C29H23F2N3O4/c30-23-11-8-18(13-24(23)31)16-34-12-4-7-22(29(34)37)28(36)33-26(19-5-2-1-3-6-19)17-38-21-10-9-20-14-27(35)32-25(20)15-21/h1-13,15,26H,14,16-17H2,(H,32,35)(H,33,36)/t26-/m0/s1ONKYDGNPFXINHC-SANMLTNESA-Nc1ccc(cc1)[C@H](COc2ccc3c(c2)NC(=O)C3)NC(=O)c4cccn(c4=O)Cc5ccc(c(c5)F)F
322MetforminC4H11N5 129.16AMPOuyang J. (2010) J. Biol. Chem. 2011 Jan. 7 286(1) 1-11Sigma1115-70-4InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)XZWYZXLIPXDOLR-UHFFFAOYSA-N4091CN(C)C(=N)N=C(N)N
170MK-2206C25H21N5O.2HCl480.39PKBHui-Fang Li (2009) Radiation Oncology 4 43Selleck1032350-13-2InChI=1S/C25H21N5O.2ClH/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31;;/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31);2*1HHWUHTJIKQZZBRA-UHFFFAOYSA-N46930998C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N.Cl.Cl
77ML-7, HydrochlorideC15H17IN2O2S • HCl452.7MLCKKrarup T. (1998) Am. J. Physiol. 275 C239Saitoh M. (1987) J. Biol. Chem. 262 7796WO1999041984Merck (Calbiochem)110448-33-4InChI=1S/C15H17IN2O2S.ClH/c16-14-6-1-5-13-12(14)4-2-7-15(13)21(19, 20)18-10-3-8-17-9-11-18;/h1-2,4-7,17H,3,8-11H2;1HKDDALCDYHZIZMH-UHFFFAOYSA-N9803932C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CC=C3I.Cl
78ML-9, HydrochlorideC15H17ClN2O2S • HCl361.3MLCKReig J.A. (1993) Neurochem. Res. 18 317Nagatsu T. (1987) Biochem. Biophys. Res. Commun. 143 1045WO1999041984Merck (Calbiochem)105637-50-1InChI=1S/C15H17ClN2O2S.ClH/c16-14-6-1-5-13-12(14)4-2-7-15(13)21(19,20)18-10-3-8-17-9-11-18;/h1-2,4-7,17H,3,8-11H2;1HZNRYCIVTNLZOGI-UHFFFAOYSA-N108047C1CNCCN(C1)S(=O)(=O)C2=CC=CC3=C2C=CC=C3Cl.Cl
351MLi-2C21H25N5O2LRRK2Matthew J. Fell (2015) Journal of Pharmacology and Experimental Therapeutics 355(3) 397-409WO2014134774InChI=1S/C21H25N5O2/c1-13-10-26(11-14(2)27-13)19-9-18(22-12-23-19)20-16-8-15(28-21(3)6-7-21)4-5-17(16)24-25-20/h4-5,8-9,12-14H,6-7,10-11H2,1-3H3,(H,24,25)ATUUNJCZCOMUKD-UHFFFAOYSA-NCC1CN(CC(O1)C)c2cc(ncn2)c3c4cc(ccc4[nH]n3)OC5(CC5)C
134MLN120BC19H17Cl3N4O2439.72IKKbNagashima K. Fraser C.C. (2006) Blood 107 4266-4273Catley M.C. Newton R. (2006) Mol.Pharmacol. 70 697-705
171MLN4924C21H26ClN5O4S479.98NEDD8-activating enzymeTeresa A. Soucy (2009) Nature 458 732-736 Active Biochem905579-51-3InChI=1S/C21H25N5O4S/c22-31(28,29)30-11-14-9-15(10-19(14)27)26-8-7-17-20(23-12-24-21(17)26)25-18-6-5-13-3-1-2-4-16(13)18/h1-4,7-8,12,14-15,18-19,27H,5-6,9-11H2,(H2,22,28,29)(H,23,24,25)/t14-,15+,18-,19-/m0/s1MPUQHZXIXSTTDU-QXGSTGNESA-N16720766C1CC2=CC=CC=C2C1NC3=NC=NC4=C3C=CN4C5CC(C(C5)O)COS(=O)(=O)N
178MLN9708C20H23BCl2N2O9517.12ProteasomeKupperman. E. (2010) Cancer Research 70 1970-1980Selleck1201902-80-8InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-17(29)8-20(34-21,19(31)32)7-16(27)28)25-15(26)9-24-18(30)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,30)(H,25,26)(H,27,28)(H,31,32)/t14-,20?/m0/s1YTXSYWAKVMZICI-PVCZSOGJSA-N49867936B1(OC(=O)CC(O1)(CC(=O)O)C(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl
300MRT199665C28H31N5O2.ClH506.04MARKClark K. (2012) Proc Natl Acad Sci USA 109(42) 16986-91WO2009152027InChI=1S/C28H31N5O2.ClH/c1-28(2)22-16-29-27(30-19-8-5-7-18(15-19)17-32-13-3-4-14-32)31-25(22)33(26(28)35)23-12-11-21-20(23)9-6-10-24(21)34;/h5-10,15-16,23,34H,3-4,11-14,17H2,1-2H3,(H,29,30,31);1HSRMFZWKBYMJXKK-UHFFFAOYSA-NCC1(c2cnc(nc2N(C1=O)C3CCc4c3cccc4O)Nc5cccc(c5)CN6CCCC6)C.Cl
202MRT67307C26H36N6O2464.60IKKε, TBK1Clark K. (2011) Biochem. J. 434 93-104Sigma1190378-57-4InChI=1S/C26H36N6O2/c33-25(21-5-2-6-21)28-11-3-10-27-24-23(20-8-9-20)17-29-26(31-24)30-22-7-1-4-19(16-22)18-32-12-14-34-15-13-32/h1,4,7,16-17,20-21H,2-3,5-6,8-15,18H2,(H,28,33)(H2,27,29,30,31)UKBGBACORPRCGG-UHFFFAOYSA-N44464263C1CC(C1)C(=O)NCCCNC2=NC(=NC=C2C3CC3)NC4=CC=CC(=C4)CN5CCOCC5
209MSC 2032964AC16H13F3N6O362.31ASK1Guo X. (2010) EMBO Molecular Medicine 2 504-515InChI=1S/C16H13F3N6O/c17-16(18,19)10-6-12(21-11-3-4-11)25-13(7-10)22-15(24-25)23-14(26)9-2-1-5-20-8-9/h1-2,5-8,11,21H,3-4H2,(H,23,24,26)XUKGFHHTSUKORV-UHFFFAOYSA-Nc1cc(cnc1)C(=O)Nc2nc3cc(cc(n3n2)NC4CC4)C(F)(F)F
80Necrostatin-1 (Nec-1)C13H13N3OS259.33RIP Degterev A. Hitomi J. (2008) Nature Chemical Biology 4 313-321WO2013013826Merck (Calbiochem)4311-88-0InChI=1S/C13H13N3OS/c1-16-12(17)11(15-13(16)18)6-8-7-14-10-5-3-2-4-9(8)10/h2-5,7,11,14H,6H2,1H3,(H,15,18)TXUWMXQFNYDOEZ-UHFFFAOYSA-N2828334CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32
81Nectrostatin-1 (Nec-1 inactive analog)C12H11N3OS245.3RIPDegterev A. Hitomi J. (2008) Nature Chemical Biology 4 313-321WO2007075772Merck (Calbiochem)64419-92-7InChI=1S/C12H11N3OS/c16-11-10(14-12(17)15-11)5-7-6-13-9-4-2-1-3-8(7)9/h1-4,6,10,13H,5H2,(H2,14,15,16,17)/t10-/m1/s1MPLRRPKKFHUEEL-SNVBAGLBSA-N5371761c1ccc2c(c1)c(c[nH]2)C[C@@H]3C(=O)NC(=S)N3
277NG-25C29H30F3N5O2537.58TAK1Dzamko N (2012) PLoS ONE 7(6) e39132 10 1371Eduardo Pauls (2012) Journal of Biological Chemistry 287 23 19216-19228MedChem Express1315355-93-1InChI=1S/C29H30F3N5O2/c1-3-36-12-14-37(15-13-36)18-21-6-7-22(17-24(21)29(30,31)32)35-28(38)20-5-4-19(2)26(16-20)39-25-9-11-34-27-23(25)8-10-33-27/h4-11,16-17H,3,12-15,18H2,1-2H3,(H,33,34)(H,35,38)SMPGEBOIKULBCT-UHFFFAOYSA-N53340664CCN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)C3=CC(=C(C=C3)C)OC4=C5C=CNC5=NC=C4)C(F)(F)F
354NIK-Novartis-T1-7C18H14N6OS362.41NIKUS20120214762InChI=1S/C18H14N6OS/c1-18(25,16-20-8-9-26-16)6-4-12-2-3-13-14(10-12)24(11-22-13)15-5-7-21-17(19)23-15/h2-3,5,7-11,25H,1H3,(H2,19,21,23)XIQHNMVNCJQWJR-UHFFFAOYSA-NCC(C#Cc1ccc2c(c1)n(cn2)c3ccnc(n3)N)(c4nccs4)O
216Novartis 12a (PKD1)C23H29F3N6O3494.51PKD1Meredith E.L. (2010) J.Med.Chem. 53 5422-5438
82NVP-BEZ 235C30H25Cl2N5O542.46PI3K, Akt, mTORMaira S. Stauffer F. (2008) Mol. Cancer. Ther. 7 1851-1863.WO2008064093Axon915019-65-7InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3JOGKUKXHTYWRGZ-UHFFFAOYSA-N11977753CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5
267OSU-03012C26H19F3N4O460.45PDK1Zhu J. (2004) Cancer Res. 64(12) 4309-18Selleck742112-33-0InChI=1S/C26H19F3N4O/c27-26(28,29)24-14-23(33(32-24)20-10-8-19(9-11-20)31-25(34)15-30)18-7-12-22-17(13-18)6-5-16-3-1-2-4-21(16)22/h1-14H,15,30H2,(H,31,34)YULUCECVQOCQFQ-UHFFFAOYSA-N10027278C1=CC=C2C(=C1)C=CC3=C2C=CC(=C3)C4=CC(=NN4C5=CC=C(C=C5)NC(=O)CN)C(F)(F)F
313OTSSP167C25H28Cl2N4O2487.42MELKSelleckInChI=1S/C25H28Cl2N4O2/c1-14(32)18-12-28-22-9-8-21(16-10-19(26)25(33)20(27)11-16)30-24(22)23(18)29-17-6-4-15(5-7-17)13-31(2)3/h8-12,15,17,33H,4-7,13H2,1-3H3,(H,28,29)/t15-,17-DKZYXHCYPUVGAF-JCNLHEQBSA-NCC(=O)c1c(c2nc(ccc2nc1)c3cc(c(c(c3)Cl)O)Cl)N[C@H]4CC[C@@H](CC4)CN(C)C
288ParthenolideC15H20O3248.32IKKβKwok B.H. (2001) Chem. Biol. 8 759-766Sigma20554-84-1InChI=1S/C15H20O3/c1-9-5-4-8-15(3)13(18-15)12-11(7-6-9)10(2)14(16)17-12/h5,11-13H,2,4,6-8H2,1,3H3/b9-5+/t11-,12-,13-,15+/m0/s1KTEXNACQROZXEV-SLXBATTESA-N6473881CC1=CCCC2(C(O2)C3C(CC1)C(=C)C(=O)O3)C
211PCI-32765 (Ibrutinib)C25H24N6O2440.5BtkHonigberg L.A. (2010) Proc Natl Acad Sci 107 13075-13080Selleckchem936563-96-1InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1XYFPWWZEPKGCCK-GOSISDBHSA-N24821094C=CC(=O)N1CCCC(C1)N2C3=C(C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=NC=N3)N
206PD 0325901C16H14F3IN2O4482.19MEK1Bain J. (2007) Biochem J. 408 297–315.Barrett SD. (2008) Bioorg. Med. Chem. Lett. 18 6501-6504.WO2002006213Axon391210-10-9InChI=1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1SUDAHWBOROXANE-SECBINFHSA-N9826528C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOCC(CO)O
213PD 0325901-Cl (CI-1055-R)C16H14O4N2F2ClI498.65MEK1WO2002006213391210-10-9InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)AHJRHEGDXFFMBM-UHFFFAOYSA-N5330286CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
214PD 0325901-Cl (CI-1055-Racemic mix of isomers)C16H14O4N2F2ClI498.65MEK1WO2002006213391210-10-9InChI=1S/C16H14ClF2IN2O4/c17-11-5-8(20)1-4-13(11)21-15-10(2-3-12(18)14(15)19)16(25)22-26-7-9(24)6-23/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m0/s1 CopyFCADPEDUULETPK-VIFPVBQESA-NC1=CC(=C(C=C1I)Cl)NC2=C(C=CC(=C2F)F)C(=O)NOC[C@H](CO)O
83PD 0325901-Cl (CI-1055-S)C16H14O4N2F2ClI498.65MEK1WO2002006213Caymanchem391210-10-9InChI=1S/C16H14ClF2IN2O4/c17-11-5-8(20)1-4-13(11)21-15-10(2-3-12(18)14(15)19)16(25)22-26-7-9(24)6-23/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m0/s1 FCADPEDUULETPK-VIFPVBQESA-N160968186C1=CC(=C(C=C1I)Cl)NC2=C(C=CC(=C2F)F)C(=O)NOC[C@H](CO)O
160PD 0332991C24H30ClN7O2483.99CDK4, CDK6Toogood P.L. (2005) J.Med.Chem. 48 2388-2406.Selleck827022-32-2InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)AHJRHEGDXFFMBM-UHFFFAOYSA-N5330286CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
84PD 184352 (CI-1040)C17H14ClF2IN2O2478.66MEK1, Yes1, ERK1Mayes PA. (2013) Int J Cancer. E149-57WO1998037881Axon212631-79-3InChI=1S/C17H14ClF2IN2O2/c18-12-7-10(21)3-6-14(12)22-16-11(4-5-13(19)15(16)20)17(24)23-25-8-9-1-2-9/h3-7,9,22H,1-2,8H2,(H,23,24)GFMMXOIFOQCCGU-UHFFFAOYSA-N6918454C1CC1CONC(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)Cl
262PF3644022C21H18N4OS374.46MAPKAPK2Mourey (2010) J.Pharmacol.Exp.Ther. 333 797Tocris1276121-88-0
264PF4708671C19H21F3N6390.41S6K1Pearce (2010) Biochem.J. 431 245Tocris1255517-76-0
85PI-103C19H16N4O3348.36PI3KSamuels Y. (2004) Science 304 554WO2001083456Merck (Calbiochem)371935-74-9InChI=1S/C19H16N4O3/c24-13-4-1-3-12(11-13)17-21-15-14-5-2-6-20-19(14)26-16(15)18(22-17)23-7-9-25-10-8-23/h1-6,11,24H,7-10H2TUVCWJQQGGETHL-UHFFFAOYSA-N9884685C1COCCN1C2=NC(=NC3=C2OC4=C3C=CC=N4)C5=CC(=CC=C5)O
86PiceatannolC14H12O4244.2PKA, SYKWang B.H. (1998) Planta Med. 64 195Keely P.J. and Parise L.V. (1996) J. Biol. Chem. 271 26668WO2012021964Merck (Calbiochem)10083-24-6InChI=1S/C14H12O4/c15-11-5-10(6-12(16)8-11)2-1-9-3-4-13(17)14(18)7-9/h1-8,15-18H/b2-1+CDRPUGZCRXZLFL-OWOJBTEDSA-N667639C1=CC(=C(C=C1C=CC2=CC(=CC(=C2)O)O)O)O
87PirfenidoneC12H11NO185.23Antifibrotic agent, SAPKKehrer and Margolin (1997) Toxicol. Lett. 90 125Iyer (1999) J.Pharmacol.Exp.Ther. 289 211WO2005040758Tocris53179-13-8InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3ISWRGOKTTBVCFA-UHFFFAOYSA-N40632CC1=CN(C(=O)C=C1)C2=CC=CC=C2
294PKR InhibitorC13H8N4OS268.3PKRIngrand S (2007) FEBS Lett. 581(23):4473-8Sigma608512-97-6InChI=1S/C13H8N4OS/c18-13-8(3-7-4-14-5-15-7)11-9(17-13)1-2-10-12(11)19-6-16-10/h1-6H,(H,14,15)(H,17,18)/b8-3-VFBGXTUGODTSPK-BAQGIRSFSA-N6490494C1=CC2=C(C3=C1NC(=O)C3=CC4=CN=CN4)SC=N2
223PLX 4032 (Vemurafenib)C23H18ClF2N3O3S489.92B-RAFBollag G. (2010) Nature 467 596-9Axon1029872-54-5InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)GPXBXXGIAQBQNI-UHFFFAOYSA-N42611257CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=NC=C(C=C23)C4=CC=C(C=C4)Cl)F
88PLX 4720 (Raf Kinase Inhibitor V)C17H14ClF2N3O3S413.83B-RafTsai J. (2008) Proc Natl Acad Sci USA. 3041-6WO2011028540Merck (Calbiochem)918505-84-7InChI=1S/C17H14ClF2N3O3S/c1-2-5-27(25,26)23-13-4-3-12(19)14(15(13)20)16(24)11-8-22-17-10(11)6-9(18)7-21-17/h3-4,6-8,23H,2,5H2,1H3,(H,21,22)YZDJQTHVDDOVHR-UHFFFAOYSA-N24180719CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=NC=C(C=C23)Cl)F
89PP1C16H19N5281.36SrcHanke (1996) J.Biol.Chem. 271 695Liu (1999) Chem.Biol. 6 671WO2012109732Enzo (Alexis)172889-26-8InChI=1S/C16H19N5/c1-10-5-7-11(8-6-10)13-12-14(17)18-9-19-15(12)21(20-13)16(2,3)4/h5-9H,1-4H3,(H2,17,18,19)ZVPDNRVYHLRXLX-UHFFFAOYSA-N1400CC1=CC=C(C=C1)C2=NN(C3=C2C(=NC=N3)N)C(C)(C)C
90PP2C15H16ClN5301.77SrcKirihara T. (2013) Exp Eye Res. S0014WO2006068760Merck (Calbiochem)172889-27-9InChI=1S/C15H16ClN5/c1-15(2,3)21-14-11(13(17)18-8-19-14)12(20-21)9-4-6-10(16)7-5-9/h4-8H,1-3H3,(H2,17,18,19)PBBRWFOVCUAONR-UHFFFAOYSA-N4878CC(C)(C)N1C2=C(C(=N1)C3=CC=C(C=C3)Cl)C(=NC=N2)N
149PP242C16H16N6O308.3mTORFeldman ME (2009) PLoS Biol 7(2)Sigma1092351-67-1InChI=1S/C16H16N6O/c1-8(2)22-16-13(15(17)18-7-19-16)14(21-22)12-6-9-5-10(23)3-4-11(9)20-12/h3-8,21,23H,1-2H3,(H2,17,18,19)/b14-12-MTICIDWIKCANDD-OWBHPGMISA-N24905147CC(C)N1C2=C(C(=C3C=C4C=C(C=CC4=N3)O)N1)C(=NC=N2)N
157PP3C11H9N5211.22SrcHou (2007) Neurosci Lett 420 235Tocris5334-30-5InChI=1S/C11H9N5/c12-10-9-6-15-16(11(9)14-7-13-10)8-4-2-1-3-5-8/h1-7H,(H2,12,13,14)KKDPIZPUTYIBFX-UHFFFAOYSA-N4879C1=CC=C(C=C1)N2C3=C(C=N2)C(=NC=N3)N
91Princeton's TrkA inhibitor compound 20hC24H24BrF3N6O4S2661.52Trk AKim S.H. Tokarski J.S. (2008) Bioorg. Med. Chem. Lett. 18 634-639InChI=1S/C22H23BrN6O2S2.C2HF3O2/c1-14-5-6-15(11-16(14)21(31)29-9-7-28(8-10-29)19(30)12-24)32-20-13-25-22(33-20)27-18-4-2-3-17(23)26-18;3-2(4,5)1(6)7/h2-6,11,13H,7-10,12,24H2,1H3,(H,25,26,27);(H,6,7)DJAXVHZSKDUJHC-UHFFFAOYSA-NCc1ccc(cc1C(=O)N2CCN(CC2)C(=O)CN)Sc3cnc(s3)Nc4cccc(n4)Br.C(=O)(C(F)(F)F)O
319PRT062607C19H23N9O 393.45SYKSpurgeon S.E. (2013) J. Pharmacol Exp Ther. 2013 Feb. 344(2) 378-387Axon1370261-96-3InChI=1S/C19H23N9O/c20-15-6-1-2-7-16(15)26-19-22-11-14(17(21)29)18(27-19)25-12-4-3-5-13(10-12)28-23-8-9-24-28/h3-5,8-11,15-16H,1-2,6-7,20H2,(H2,21,29)(H2,22,25,26,27)/t15-,16+/m0/s1 TXGKRVFSSHPBAJ-JKSUJKDBSA-NC1CC[C@H]([C@H](C1)N)NC2=NC=C(C(=N2)NC3=CC(=CC=C3)N4N=CC=N4)C(=O)N
92PS-1145C17H11ClN4O322.75IKKCastro A.C. (2003) Bioorg. Med. Chem. Lett. 13 2419-2422.WO2003039545Sigma431898-65-6InChI=1S/C17H11ClN4O/c18-11-6-13-12-3-5-20-9-15(12)21-16(13)14(7-11)22-17(23)10-2-1-4-19-8-10/h1-9,21H,(H,22,23)JZRMBDHPALEPDM-UHFFFAOYSA-N9949093C1=CC(=CN=C1)C(=O)NC2=C3C(=CC(=C2)Cl)C4=C(N3)C=NC=C4
93Purvalanol AC19H25ClN6O 388.9cyclin-dependent kinasesGray N.S. (1998) Science 281 533 Merck (Calbiochem)212844-53-6InChI=1S/C19H25ClN6O/c1-11(2)15(9-27)23-19-24-17(22-14-7-5-6-13(20)8-14)16-18(25-19)26(10-21-16)12(3)4/h5-8,10-12,15,27H,9H2,1-4H3,(H2,22,23,24,25)/t15-/m0/s1PMXCMJLOPOFPBT-HNNXBMFYSA-N456214CC(C)C(CO)NC1=NC2=C(C(=N1)NC3=CC(=CC=C3)Cl)N=CN2C(C)C
181Purvalanol BC20H25ClN6O3432.9CDKWO1999007705Sigma212844-54-7InChI=1S/C20H25ClN6O3/c1-10(2)15(8-28)24-20-25-17(16-18(26-20)27(9-22-16)11(3)4)23-12-5-6-13(19(29)30)14(21)7-12/h5-7,9-11,15,28H,8H2,1-4H3,(H,29,30)(H2,23,24,25,26)/t15-/m0/s1ZKDXRFMOHZVXSG-HNNXBMFYSA-N448991CC(C)C(CO)NC1=NC2=C(C(=N1)NC3=CC(=C(C=C3)C(=O)O)Cl)N=CN2C(C)C
342QNZC22H20N4O356.4NF-κBCayman545380-34-5InChI=1S/C22H20N4O/c23-17-8-11-21-20(14-17)22(26-15-25-21)24-13-12-16-6-9-19(10-7-16)27-18-4-2-1-3-5-18/h1-11,14-15H,12-13,23H2,(H,24,25,26)IBAKVEUZKHOWNG-UHFFFAOYSA-N509554NC1=CC2=C(N=CN=C2NCCC3=CC=C(OC4=CC=CC=C4)C=C3)C=C1
156QuercetagetinC15H10O8318.3 PIM1Holder S. (2007) Mol. Cancer Ther. 6 163 Merck (Calbiochem)90-18-6InChI=1S/C15H10O8/c16-6-2-1-5(3-7(6)17)15-14(22)13(21)10-9(23-15)4-8(18)11(19)12(10)20/h1-4,16-20,22HZVOLCUVKHLEPEV-UHFFFAOYSA-N5281680C1=CC(=C(C=C1C2=C(C(=O)C3=C(C(=C(C=C3O2)O)O)O)O)O)O
175R-406C23H24FN5O5469.46SYKBraselmann S. (2006) J Pharmacol Exp Ther. 319(3) 998-1008Selleck841290-80-0InChI=1S/C22H23FN6O5/c1-22(2)20(30)28-19-13(34-22)6-7-16(27-19)26-18-12(23)10-24-21(29-18)25-11-8-14(31-3)17(33-5)15(9-11)32-4/h6-10H,1-5H3,(H3,24,25,26,27,28,29,30)NHHQJBCNYHBUSI-UHFFFAOYSA-N11213558CC1(C(=O)NC2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)C
94RapamycinC51H79NO13914.2p70S6KPowell D.J. (2003) Mol. Cell Biol. 23 7794Braun W. (1995) FASEB J. 9 63Merck (Calbiochem)53123-88-9InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1QFJCIRLUMZQUOT-HPLJOQBZSA-N5284616CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC
95ResveratrolC14H12O3228.2cyclo-oxygenase 1Lin H.Y. (2002) J. Urol. 168 748Klabunde T. (2000) Nat. Struct. Biol. 7 312Merck (Calbiochem)501-36-0InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+LUKBXSAWLPMMSZ-OWOJBTEDSA-N445154C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O
174Rigel TRAF6 InhibitorC16H12ClF4N5O3S465.81TRAF6WO2008115259InChI=1S/C16H12ClF4N5O3S/c17-10-7-9(16(19,20)21)8-22-15(10)25-3-5-26(6-4-25)30(27,28)12-2-1-11(18)13-14(12)24-29-23-13/h1-2,7-8H,3-6H2YMUOIWDXLVPLHO-UHFFFAOYSA-Nc1cc(c2c(c1F)non2)S(=O)(=O)N3CCN(CC3)c4c(cc(cn4)C(F)(F)F)Cl
96RO-31-8220C25H23N5O2S • CH4O3S553.7PKCTrapp J. (2006) J. Med. Chem. 49 7307-16Powell D.J. (2003) Mol. Cell Biol. 23 7794Merck (Calbiochem)125314-64-9InChI=1S/C25H23N5O2S.CH4O3S/c1-29-13-17(15-7-2-4-9-19(15)29)21-22(24(32)28-23(21)31)18-14-30(11-6-12-33-25(26)27)20-10-5-3-8-16(18)20;1-5(2,3)4/h2-5,7-10,13-14H,6,11-12H2,1H3,(H3,26,27)(H,28,31,32);1H3,(H,2,3,4)SAWVGDJBSPLRRB-UHFFFAOYSA-N11628205CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)CCCSC(=N)N.CS(=O)(=O)O
339RO-3306C₁₈H₁₃N₃OS₂351.5Cdk1Vassilev, L.T. (2006) Proc. Natl. Acad. Sci. USA 103 10660Calbiochem872573-93-8InChI=1S/C18H13N3OS2/c22-17-16(24-18(21-17)20-11-14-4-2-8-23-14)10-12-5-6-15-13(9-12)3-1-7-19-15/h1-10H,11H2,(H,20,21,22)XOLMRFUGOINFDQ-UHFFFAOYSA-N71433937C1=CC2=C(C=CC(=C2)C=C3C(=O)N=C(S3)NCC4=CC=CS4)N=C1
97RoscovitineC19H26N6O354.5CDKDe Azevedo W.F. (1997) Eur. J. Biochem. 243 518Meijer L. (1997) Eur. J. Biochem. 243 527Merck (Calbiochem)186692-46-6InChI=1S/C19H26N6O/c1-4-15(11-26)22-19-23-17(20-10-14-8-6-5-7-9-14)16-18(24-19)25(12-21-16)13(2)3/h5-9,12-13,15,26H,4,10-11H2,1-3H3,(H2,20,22,23,24)/t15-/m1/s1BTIHMVBBUGXLCJ-OAHLLOKOSA-N160355CCC(CO)NC1=NC2=C(C(=N1)NCC3=CC=CC=C3)N=CN2C(C)C
98RottlerinC30H28O8516.5PKCVillalba M. (1999) J. Immunol. 163 5813Gschwendt M. (1994) Biochem. Biophys. Res. Commun. 199 93Merck (Calbiochem)82-08-6InChI=1S/C30H28O8/c1-15-24(33)19(27(36)22(16(2)31)25(15)34)14-20-26(35)18-12-13-30(3,4)38-29(18)23(28(20)37)21(32)11-10-17-8-6-5-7-9-17/h5-13,33-37H,14H2,1-4H3/b11-10+DEZFNHCVIZBHBI-ZHACJKMWSA-N5281847CC1=C(C(=C(C(=C1O)C(=O)C)O)CC2=C(C3=C(C(=C2O)C(=O)C=CC4=CC=CC=C4)OC(C=C3)(C)C)O)O
189Ruxolitinib (INCB18424)C17H18N6306.37JAKLawrence J Wilson (2010) Expert Opinion on Therapeutic Patents May 20(5) 609-623WO2008157208Selleck941678-49-5InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1HFNKQEVNSGCOJV-OAHLLOKOSA-N25126798C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
278Saracatinib (AZD0530)C27H32ClN5O5542.03SrcH Laurent (2006) J. Med. Chem. 49(22) 6465-6488Selleck379231-04-6InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)OUKYUETWWIPKQR-UHFFFAOYSA-N10302451CN1CCN(CC1)CCOC2=CC(=C3C(=C2)N=CN=C3NC4=C(C=CC5=C4OCO5)Cl)OC6CCOCC6
99SB-202190C20H14FN3O331.3p38 MAPKDavies S.P. (2000) Biochem. J. 351 95Ajizian S.J. (1999) J. Infect. Dis. 179 939Merck (Calbiochem)152121-30-7InChI=1S/C20H14FN3O/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(25)8-4-15/h1-12,23-24HNJNKPVPFGLGHPA-UHFFFAOYSA-N5353940C1=CC(=O)C=CC1=C2NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F
100SB-203580C21H16N3OSF377.4p38 MAPKPowell D.J. (2003) Mol. Cell Biol. 23 7794Davies S.P. (2000) Biochem. J. 351 95Merck (Calbiochem)152121-47-6InChI=1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25)CDMGBJANTYXAIV-UHFFFAOYSA-N176155CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F
101SB-216763C19H12Cl2N2O2371.22GSK3Coghlan (2000) Chem.Biol. 7 793Liang (2006) J.Biol.Chem. 282 3904Tocris280744-09-4InChI=1S/C19H12Cl2N2O2/c1-23-9-13(11-4-2-3-5-15(11)23)17-16(18(24)22-19(17)25)12-7-6-10(20)8-14(12)21/h2-9H,1H3,(H,22,24,25)JCSGFHVFHSKIJH-UHFFFAOYSA-N176158CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=C(C=C(C=C4)Cl)Cl
102SB-415286C16H10ClN3O5359.73GSK3Coghlan (2000) Chem.Biol. 7 793Cross (2001) J.Neurochem. 77 94Tocris264218-23-7InChI=1S/C16H10ClN3O5/c17-10-7-8(5-6-12(10)21)18-14-13(15(22)19-16(14)23)9-3-1-2-4-11(9)20(24)25/h1-7,21H,(H2,18,19,22,23)PQCXVIPXISBFPN-UHFFFAOYSA-N4210951C1=CC=C(C(=C1)C2=C(C(=O)NC2=O)NC3=CC(=C(C=C3)O)Cl)[N+](=O)[O-]
161SB-431542C22H16N4O3 · xH2O384.39ALKInman et al (2002) Mol.Pharmacol. 62 65Sigma301836-41-9InChI=1S/C22H16N4O3/c23-21(27)13-4-6-14(7-5-13)22-25-19(20(26-22)16-3-1-2-10-24-16)15-8-9-17-18(11-15)29-12-28-17/h1-11H,12H2,(H2,23,27)(H,25,26)FHYUGAJXYORMHI-UHFFFAOYSA-N4521392C1OC2=C(O1)C=C(C=C2)C3=C(NC(=N3)C4=CC=C(C=C4)C(=O)N)C5=CC=CC=N5
188SB-505124C20H21N3O2 · xHCl · yH2O335.40ALKByfield (2004) Mol.Pharmacol. 65 744Sigma694433-59-5InChI=1S/C20H21N3O2/c1-12-6-5-7-14(21-12)18-17(22-19(23-18)20(2,3)4)13-8-9-15-16(10-13)25-11-24-15/h5-10H,11H2,1-4H3,(H,22,23)WGZOTBUYUFBEPZ-UHFFFAOYSA-N9858940WGZOTBUYUFBEPZ-UHFFFAOYSA-N
265SB-590885C27H27N5O2453.54B-RafKing (2006) Cancer Res. 66 11100Tocris405554-55-4InChI=1S/C27H27N5O2/c1-32(2)15-16-34-22-7-3-19(4-8-22)27-29-25(18-11-13-28-14-12-18)26(30-27)21-5-9-23-20(17-21)6-10-24(23)31-33/h3-5,7-9,11-14,17,28H,6,10,15-16H2,1-2H3,(H,29,30)/b26-21+DPCXEUSDRQOOGZ-YYADALCUSA-N11465183CN(C)CCOC1=CC=C(C=C1)C2=NC(=C3C=CC4=C(CCC4=C3)N=O)C(=C5C=CNC=C5)N2
266SB-747651AC16H22N8O342.40Naqvi (2012) Biochem. J. 441 (347–357)AxonInChI=1S/C16H22N8O/c1-2-24-14-10(8-20-11-3-5-18-6-4-11)7-19-9-12(14)21-16(24)13-15(17)23-25-22-13/h7,9,11,18,20H,2-6,8H2,1H3,(H2,17,23)MBCJUIJWPYUEBX-UHFFFAOYSA-N11393719CCN1C2=C(C=NC=C2CNC3CCNCC3)N=C1C4=NON=C4N
103SC514 ( IKK-2 Inhibitor)C9H8N2OS2224.3IKK2Baxter A. (2004) Bioorg. Med. Chem. Lett. 14 2817Kishore N. (2003) J. Biol. Chem. 278 32861Merck (Calbiochem)354812-17-2InChI=1S/C9H8N2OS2/c10-6-3-7(5-1-2-13-4-5)14-8(6)9(11)12/h1-4H,10H2,(H2,11,12)BMUACLADCKCNKZ-UHFFFAOYSA-N2807869C1=CSC=C1C2=CC(=C(S2)C(=O)N)N
344SGK-Sanofi-14iC18H15ClN6O3S430,.87SGKHalland, N (2015) ACS Medicinal Chemistry Letters 6 73-78
343SGK1-Sanofi-14gC17H12Cl2N6O2S435.29SGKHalland, N (2015) ACS Medicinal Chemistry Letters 6 73-78
349SGK1-Sanofi-14hC17H12Cl2N6O2S435.29SGK Halland, N (2015) ACS Medicinal Chemistry Letters , 6,73-78
345SGK1-Sanofi-14nC17H12CIFN6O2S418.83SGKHalland, N (2015) ACS Medicinal Chemistry Letters 6 73-78
352SGK1-Sanofi-308-RC23H23FN6O4S498.53SGK1WO2014140065InChI=1S/C23H23FN6O4S/c1-14-2-7-19(24)20(10-14)35(31,32)30-16-5-3-15(4-6-16)21-27-22-18(12-26-29-22)23(28-21)34-13-17-11-25-8-9-33-17/h2-7,10,12,17,25,30H,8-9,11,13H2,1H3,(H,26,27,28,29)/t17-/m1/s1UAVUYSNDFXWICV-QGZVFWFLSA-NCc1ccc(c(c1)S(=O)(=O)Nc2ccc(cc2)c3nc4c(cn[nH]4)c(n3)OC[C@H]5CNCCO5)F
353SGK1-Sanofi-308-SC23H23FN6O4S498.53SGK1WO2014140065InChI=1S/C23H23FN6O4S/c1-14-2-7-19(24)20(10-14)35(31,32)30-16-5-3-15(4-6-16)21-27-22-18(12-26-29-22)23(28-21)34-13-17-11-25-8-9-33-17/h2-7,10,12,17,25,30H,8-9,11,13H2,1H3,(H,26,27,28,29)/t17-/m0/s1UAVUYSNDFXWICV-KRWDZBQOSA-NCc1ccc(c(c1)S(=O)(=O)Nc2ccc(cc2)c3nc4c(cn[nH]4)c(n3)OC[C@@H]5CNCCO5)F
356SGK1-Sanofi-ex.290-RC24H25ClN6O5S545.01SGK1WO2014140065InChI=1S/C24H25ClN6O5S/c1-14-21-23(30-29-14)27-22(28-24(21)36-13-18-12-26-9-10-35-18)15-3-5-16(6-4-15)31-37(32,33)20-11-17(34-2)7-8-19(20)25/h3-8,11,18,26,31H,9-10,12-13H2,1-2H3,(H,27,28,29,30)/t18-/m1/s1JOEDMMFGXYMXAW-GOSISDBHSA-NCc1c2c([nH]n1)nc(nc2OC[C@H]3CNCCO3)c4ccc(cc4)NS(=O)(=O)c5cc(ccc5Cl)OC
355SGK1-Sanofi-ex.290-SC24H25ClN6O5S545.01SGK1WO2014140065InChI=1S/C24H25ClN6O5S/c1-14-21-23(30-29-14)27-22(28-24(21)36-13-18-12-26-9-10-35-18)15-3-5-16(6-4-15)31-37(32,33)20-11-17(34-2)7-8-19(20)25/h3-8,11,18,26,31H,9-10,12-13H2,1-2H3,(H,27,28,29,30)/t18-/m0/s1JOEDMMFGXYMXAW-SFHVURJKSA-NCc1c2c([nH]n1)nc(nc2OC[C@@H]3CNCCO3)c4ccc(cc4)NS(=O)(=O)c5cc(ccc5Cl)OC
112SL-327 (MEK1-2 Inhibitor)C16H12F3N3S335.4MEK1, MEK2Hetman M. (2002) J. Biol. Chem. 277 49577Ohno M. (2001) Nat. Neurosci. 4 1238Tocris305350-87-2JLOXTZFYJNCPIS-FYWRMAATSA-NJLOXTZFYJNCPIS-FYWRMAATSA-N9549284C1=CC=C(C(=C1)C(=C(N)SC2=CC=C(C=C2)N)C#N)C(F)(F)F
111SL0101-1C25H24O12516.46RSKSmith (2005) Cancer Res. 65 1027Goden Sayeski (2006) Am. J. Cell. Physiol. 291 1308Tocris77307-50-7InChI=1S/C25H24O12/c1-10-21(34-11(2)26)24(35-12(3)27)20(32)25(33-10)37-23-19(31)18-16(30)8-15(29)9-17(18)36-22(23)13-4-6-14(28)7-5-13/h4-10,20-21,24-25,28-30,32H,1-3H3/t10-,20+,21-,24-,25-/m0/s1SXOZSDJHGMAEGZ-IGKKHSBFSA-N10459196CC1C(C(C(C(O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)O)OC(=O)C)OC(=O)C
185Sodium salicylateHOC6H4COONa160.10p38Schwenger P. (1998) Mol Cell Biol. Jan 18(1) 78-84Sigma54-21-7InChI=1S/C7H6O3.Na/c8-6-4-2-1-3-5(6)7(9)10;/h1-4,8H,(H,9,10);/q;+1/p-1ABBQHOQBGMUPJH-UHFFFAOYSA-M16760658C1=CC=C(C(=C1)C(=O)[O-])O.[Na+]
113Sodium valproateC8H15NaO2166.19Histone deacetylasePhiel (2001) J.Biol.Chem. 276 36734Kostrouchova (2007) Folia Biologica 53 37Sigma1069-66-5InChI=1S/C8H16O2.Na/c1-3-5-7(6-4-2)8(9)10;/h7H,3-6H2,1-2H3,(H,9,10);/q;+1/p-1AEQFSUDEHCCHBT-UHFFFAOYSA-M16760703CCCC(CCC)C(=O)[O-].[Na+]
114SP600125 (JNK Inhibitor II, SAPK Inhibitor II)C14H8N2O220.2JNKShin M. Boyd Y.D. (2002) Biochim. Biophys. Acta 1589 311Bennett B.L. (2001) Proc. Natl. Acad. Sci. USA 98 13681Merck (Calbiochem)129-56-6InChI=1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7H,(H,15,16)ACPOUJIDANTYHO-UHFFFAOYSA-N8515C1=CC=C2C(=C1)C3=NNC4=CC=CC(=C43)C2=O
179Sphingosine Kinase Inhibitor (SKI II)C15H11ClN2OS339.2 SphK1French (2003) Cancer Res. 63 5962.French (2006) J.Pharmacol.Exp.Ther. 318 596Merck (Calbiochem)1177741-83-1InChI=1S/C15H11ClN2OS.ClH/c16-11-3-1-10(2-4-11)14-9-20-15(18-14)17-12-5-7-13(19)8-6-12;/h1-9,19H,(H,17,18);1HZDRVLAOYDGQLFI-UHFFFAOYSA-N16760659C1=CC(=CC=C1C2=CSC(=N2)NC3=CC=C(C=C3)O)Cl.Cl
115SRC Inhibitor 1C22H19N3O3373.4SrcTian G. (2001) Biochemistry 40 7084Merck (Calbiochem)179248-59-0InChI=1S/C22H19N3O3/c1-26-20-12-18-19(13-21(20)27-2)23-14-24-22(18)25-15-8-10-17(11-9-15)28-16-6-4-3-5-7-16/h3-14H,1-2H3,(H,23,24,25)DMWVGXGXHPOEPT-UHFFFAOYSA-N1474853COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=C(C=C3)OC4=CC=CC=C4)OC
116SRT 1720C27H24F3N7O3S583.59SIRT1Milne J.C. Lambert P.D. Schenk S. (2007) Nature 450 712-716Cayman1001645-58-4InChI=1S/C25H23N7OS.ClH/c33-24(22-13-27-20-7-3-4-8-21(20)28-22)29-19-6-2-1-5-18(19)23-15-32-17(16-34-25(32)30-23)14-31-11-9-26-10-12-31;/h1-8,13,15-16,26H,9-12,14H2,(H,29,33);1HDTGRRMPPXCRRIM-UHFFFAOYSA-N25232708C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl
208StaurosporineC28H26N4O3466.54Broad spectrumBoix J. (1997) Neuropharmacology 36 811-821Wiesner D.A. and Dawson G. (1996) J. Neurochem. 66 1418-1425LC labs62996-74-1InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m0/s1HKSZLNNOFSGOKW-HMWZOHBLSA-N451705CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)NC)OC
117STO 609C19H10N2O3 • CH3CO2H374.4CaMKKLevine Y. (2007) J. Biol. Chem. 282 20351Tokumitsu H. (2003) J. Biol. Chem. 278 10908Merck (Calbiochem)52029-86-4InChI=1S/C19H10N2O3/c22-18-13-5-3-4-10-11(19(23)24)8-9-12(16(10)13)17-20-14-6-1-2-7-15(14)21(17)18/h1-9H,(H,23,24)/p-1MYKOWOGZBMOVBJ-UHFFFAOYSA-M51371511C1=CC=C2C(=C1)N=C3N2C(=O)C4=CC=CC5=C(C=CC3=C54)C(=O)[O-]
324STOCK1S-50699C29H31IN2S2598.60WNKMori T. (2013) Biochem J. 1 455(3) 339-45MolportInChI=1S/C29H31N2S2.HI/c1-4-30-24-12-6-8-14-26(24)32-28(30)16-10-11-22-17-21(3)18-23(19-22)20-29-31(5-2)25-13-7-9-15-27(25)33-29;/h6-16,19-21H,4-5,17-18H2,1-3H3;1H/q+1;/p-1JNEYCFRQMCKLHV-UHFFFAOYSA-M5332561CCN1C2=CC=CC=C2SC1=CC3=CC(=CC=CC4=[N+](C5=CC=CC=C5S4)CC)CC(C3)C.[I-]
323STOCK2S-26016C20H19N3O2333.38976WNKMori T. (2013) Biochem J. 1 455(3) 339-45InterBioScreenInChI=1S/C20H19N3O2/c1-2-24-14-6-8-18-17(11-14)20(21)16-7-5-13(10-19(16)23-18)22-12-15-4-3-9-25-15/h3-11,22H,2,12H2,1H3,(H2,21,23)PGNWQNJXXLPZEL-UHFFFAOYSA-N3135086CCOc1ccc2c(c1)c(N)c1c(n2)cc(cc1)NCc1ccco1
118SU-5416 (VEGFR2 Kinase Inhibitor III)C15H14N2O238.3VEGF-RTille J.C. (2003) Exp. Cell Res. 285 286Itokawa T. (2002) Mol. Cancer Ther. 1 295Tocris204005-46-9InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-WUWDLXZGHZSWQZ-WQLSENKSSA-N5329098CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C
119SU-6656C19H21N3O3S371.5SrcBowman T. (2001) Proc. Natl. Acad. Sci. USA 98 7319 Blake R.A. (2000) Mol. Cell. Biol. 20 9018Sigma330161-87-0InChI=1S/C19H21N3O3S/c1-22(2)26(24,25)14-7-8-18-15(11-14)16(19(23)21-18)10-13-9-12-5-3-4-6-17(12)20-13/h7-11,20H,3-6H2,1-2H3,(H,21,23)/b16-10-LOGJQOUIVKBFGH-YBEGLDIGSA-N5312137CN(C)S(=O)(=O)C1=CC2=C(C=C1)NC(=O)C2=CC3=CC4=C(N3)CCCC4
120SU-6668C18H18N2O3310.35AuroraGodl K. (2005) Cancer Res. 65 6919-6926.Tocris252916-29-3InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9-NHFDRBXTEDBWCZ-ZROIWOOFSA-N5329099CC1=C(NC(=C1CCC(=O)O)C)C=C2C3=CC=CC=C3NC2=O
155SulfasalazineC18H14N4O5S398.39glutathione-S-transferaseLiptay S. (1999) Br. J. Pharmacol. 128 1361Volin M.V. (1999) Arthritis Rheum. 42 1927Sigma599-79-1InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,20H,(H,19,22)(H,24,25)/b21-13-OQANPHBRHBJGNZ-BKUYFWCQSA-N5359476C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)NN=C3C=CC(=O)C(=C3)C(=O)O
151Sunitinib (SU-11248)C22H27FN4O2398.47RTKSakamoto K. M. (2004) Curr Opin Investig Drugs 5(12) 1329-39Axon341031-54-7InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-WINHZLLDWRZWRT-ATVHPVEESA-N5329102CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C
139SYK Inhibitor IC18H15N3O3S353.4SYKLai J.Y. (2003) Bioorg. Med. Chem. Lett. 13 3111Merck (Calbiochem)622387-85-3InChI=1S/C18H15N3O3S/c1-21-10-11(13-4-2-3-5-17(13)21)8-15-14-9-12(25(19,23)24)6-7-16(14)20-18(15)22/h2-10H,1H3,(H,20,22)(H2,19,23,24)/b15-8-MLKHXLFEYOOYEY-NVNXTCNLSA-N6419747CN1C=C(C2=CC=CC=C21)C=C3C4=C(C=CC(=C4)S(=O)(=O)N)NC3=O
140SYK Inhibitor IIC14H15F3N6O • 2HCl•2H2O449.3SYKHisamichi H. (2005) Bioorg. Med. Chem. 13 4936Merck (Calbiochem)227449-73-2InChI=1S/C14H15F3N6O.2ClH.2H2O/c15-14(16,17)8-2-1-3-9(6-8)22-12-10(11(19)24)7-21-13(23-12)20-5-4-18;;;;/h1-3,6-7H,4-5,18H2,(H2,19,24)(H2,20,21,22,23);2*1H;2*1H2LCACSMNPIITJGG-UHFFFAOYSA-N16760670C1=CC(=CC(=C1)NC2=NC(=NC=C2C(=O)N)NCCN)C(F)(F)F.O.O.Cl.Cl
141SYK Inhibitor IIIC9H7NO4193.2 SYKWang W.Y. (2006) Mol. Pharmacol. 70 1380Merck (Calbiochem)1485-00-3InChI=1S/C9H7NO4/c11-10(12)4-3-7-1-2-8-9(5-7)14-6-13-8/h1-5H,6H2/b4-3+KFLWBZPSJQPRDD-ONEGZZNKSA-N672296C1OC2=C(O1)C=C(C=C2)C=C[N+](=O)[O-]
142SYK Inhibitor IV (BAY 61-3606)C20H18N6O3 • HCl • H2O444.9SYKYamamoto N. (2003) J Pharmacol Exp Ther 306 1174Merck (Calbiochem)732983-37-8InChI=1S/C20H18N6O3.2ClH/c1-28-15-6-5-12(10-16(15)29-2)14-11-17-22-8-9-26(17)20(24-14)25-19-13(18(21)27)4-3-7-23-19;;/h3-11H,1-2H3,(H2,21,27)(H,23,24,25);2*1HSPMFEULFGGPQLN-UHFFFAOYSA-N11784504COC1=C(C=C(C=C1)C2=CC3=NC=CN3C(=N2)NC4=C(C=CC=N4)C(=O)N)OC.Cl.Cl
259TAE684C30H40ClN7O3S614.22NPM-ALKZhang J. (2012) Bioorg. Med. Chem. Lett. 22 1864–1869Galkin A.V. (2007) Proc. Natl. Acad. Sci. USA 104 (1) 270-275Axon761439-42-3InChI=1S/C30H40ClN7O3S/c1-21(2)42(39,40)28-8-6-5-7-26(28)33-29-24(31)20-32-30(35-29)34-25-10-9-23(19-27(25)41-4)37-13-11-22(12-14-37)38-17-15-36(3)16-18-38/h5-10,19-22H,11-18H2,1-4H3,(H2,32,33,34,35)QQWUGDVOUVUTOY-UHFFFAOYSA-N16038120CC(C)S(=O)(=O)C1=CC=CC=C1NC2=NC(=NC=C2Cl)NC3=C(C=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC
315Tenovin-6C25H34N4O2S454.6Cayman1011557-82-6InChI=1S/C25H34N4O2S/c1-25(2,3)19-11-9-18(10-12-19)23(31)28-24(32)27-21-15-13-20(14-16-21)26-22(30)8-6-7-17-29(4)5/h9-16H,6-8,17H2,1-5H3,(H,26,30)(H2,27,28,31,32)BVJSXSQRIUSRCO-UHFFFAOYSA-N24772043CC(C)(C)C1=CC=C(C(NC(NC2=CC=C(NC(CCCCN(C)C)=O)C=C2)=S)=O)C=C1
169TG003C13H15NO2S249.33Cdc2-like kinaseMuraki M. (2004) J. Biol. Chem. 279 24246-24254Sigma300801-52-9InChI=1S/C13H15NO2S/c1-4-14-11-8-10(16-3)5-6-12(11)17-13(14)7-9(2)15/h5-8H,4H2,1-3H3/b13-7-BGVLELSCIHASRV-QPEQYQDCSA-N1893668CCN1C2=C(C=CC(=C2)OC)SC1=CC(=O)C
263Torin1C35H28F3N5O2607.62mTORLiu Q. (2012) J Biol Chem. 287 9742-52Tocris1222998-36-8InChI=1S/C35H28F3N5O2/c1-2-32(44)42-15-13-41(14-16-42)31-11-9-26(19-28(31)35(36,37)38)43-33(45)12-8-24-20-40-30-10-7-22(18-27(30)34(24)43)25-17-23-5-3-4-6-29(23)39-21-25/h3-12,17-21H,2,13-16H2,1H3AKCRNFFTGXBONI-UHFFFAOYSA-N49836027CCC(=O)N1CCN(CC1)C2=C(C=C(C=C2)N3C(=O)C=CC4=CN=C5C=CC(=CC5=C43)C6=CC7=CC=CC=C7N=C6)C(F)(F)F
289TTT-3002LRRK2Yao C (2012) Hum Mol Genet.
205Ubiquitin E1 Inhibitor (PYR-41)C17H13N3O7 • 3H2O 425.4 Ubiquitin-E1Yang Y (2007) Cancer Res. 67 9472Merck (Calbiochem)418805-02-4InChI=1S/C17H13N3O7/c1-2-26-17(23)10-3-5-11(6-4-10)19-16(22)13(15(21)18-19)9-12-7-8-14(27-12)20(24)25/h3-9H,2H2,1H3,(H,18,21)/b13-9-ARGIPZKQJGFSGQ-LCYFTJDESA-N5335621CCOC(=O)C1=CC=C(C=C1)N2C(=O)C(=CC3=CC=C(O3)[N+](=O)[O-])C(=O)N2
122UCN-01C28H26N4O4482.5PKCReinhardt H.C. (2007) Cancer Cell 11 175Jiang X. (2004) Mol. Cancer Ther. 3 1221Sigma112953-11-4InChI=1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1PBCZSGKMGDDXIJ-HQCWYSJUSA-N72271CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)C(NC6=O)O)NC)OC
123Uo126C18H16N6S2380.48MEK1, MEK2Favata (1998) J. Biol. Chem. 273 18623Duncia (1998) Bioorg. Med. Chem. Lett. 8 2839Tocris109511-58-2InChI=1S/C18H16N6S2/c19-9-11(17(23)25-15-7-3-1-5-13(15)21)12(10-20)18(24)26-16-8-4-2-6-14(16)22/h1-8H,21-24H2/b17-11+,18-12+DVEXZJFMOKTQEZ-JYFOCSDGSA-N3006531C1=CC=C(C(=C1)N)SC(=C(C#N)C(=C(N)SC2=CC=CC=C2N)C#N)N
340VolasertibC34H50N8O3618.81PLK1Rudolph D (2009) Clin Cancer Res 15(9) 3094-3102Grinshtein N (2011) Cancer Res 71(4) 1385-1395Selleck755038-65-4InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25?,26?,28-/m1/s1SXNJFOWDRLKDSF-XKHVUIRMSA-N10461508CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C
330VPS34-IN1C21H24ClN7O425.91Vps34Bago R (2014) Biochem J.WO2012085815InChI=1S/C21H24ClN7O/c1-21(2,30)12-26-19-25-11-15(17(29-19)9-13-3-4-13)16-6-8-24-20(28-16)27-14-5-7-23-18(22)10-14/h5-8,10-11,13,30H,3-4,9,12H2,1-2H3,(H,25,26,29)(H,23,24,27,28)AWNXKZVIZARMME-UHFFFAOYSA-NCC(C)(CNc1ncc(c(n1)CC2CC2)c3ccnc(n3)Nc4ccnc(c4)Cl)O
321VPS34-IN2 (PIK-III)C17H17N7319.36PI3K, VPS34William E. Dowdle (2014) Nature Cell BiologyWO2012085815InChI=1S/C17H17N7/c18-16-21-10-13(15(23-16)9-11-1-2-11)14-5-8-20-17(24-14)22-12-3-6-19-7-4-12/h3-8,10-11H,1-2,9H2,(H2,18,21,23)(H,19,20,22,24)XXSDLQLNIVFIJI-UHFFFAOYSA-Nc1cnccc1Nc2nccc(n2)c3cnc(nc3CC4CC4)N
125VX-680C23H28N8OS464.59AuroraHarrington E.A. (2004) Nature Medicine 10 262Tocris639089-54-6InChI=1S/C23H28N8OS/c1-15-13-20(29-28-15)25-19-14-21(31-11-9-30(2)10-12-31)27-23(26-19)33-18-7-5-17(6-8-18)24-22(32)16-3-4-16/h5-8,13-14,16H,3-4,9-12H2,1-2H3,(H,24,32)(H2,25,26,27,28,29)GCIKSSRWRFVXBI-UHFFFAOYSA-N5494449CC1=CC(=NN1)NC2=NC(=NC(=C2)N3CCN(CC3)C)SC4=CC=C(C=C4)NC(=O)C5CC5
124VX-745C19H9Cl2F2N3OS436.26p38 MAPKTsai YR Epub 2013 Jan 21 Eur J Pharmacol. 2013 Feb 15 701(1-3) 96-105WO1998027098Selleck209410-46-8InChI=1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9HVEPKQEUBKLEPRA-UHFFFAOYSA-N3038525C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl
285Withaferin AC28H38O6470.6IKKβKaileh (2007) J.Biol.Chem. 282 4253Tocris5119-48-2InChI=1S/C28H38O6/c1-14-11-21(33-25(32)17(14)13-29)15(2)18-5-6-19-16-12-24-28(34-24)23(31)8-7-22(30)27(28,4)20(16)9-10-26(18,19)3/h7-8,15-16,18-21,23-24,29,31H,5-6,9-13H2,1-4H3/t15-,16-,18+,19-,20-,21+,23-,24+,26+,27-,28+/m0/s1DBRXOUCRJQVYJQ-CKNDUULBSA-N265237CC1=C(C(=O)OC(C1)C(C)C2CCC3C2(CCC4C3CC5C6(C4(C(=O)C=CC6O)C)O5)C)CO
357WNK-463C21H24F3N7O2463.46WNKYamada K (2016) Nat Chem Biol. 12(11) 896-898InChI=1S/C21H24F3N7O2/c1-20(2,3)27-17(32)15-11-25-12-31(15)14-6-8-30(9-7-14)16-5-4-13(10-26-16)18-28-29-19(33-18)21(22,23)24/h4-5,10-12,14H,6-9H2,1-3H3,(H,27,32)HWSHOMMVLGBIDN-UHFFFAOYSA-N121487936CC(C)(C)NC(=O)c1cncn1C2CCN(CC2)c3ccc(cn3)c4nnc(o4)C(F)(F)F
126Wortmannin (KY 12420)C23H24O8428.4PI3KCross M.J. (1995) J. Biol. Chem. 270 25352Nakamura I. (1995) FEBS Lett. 361 79Merck (Calbiochem)19545-26-7InChI=1S/C23H24O8/c1-10(24)30-13-7-22(2)12(5-6-14(22)25)16-18(13)23(3)15(9-28-4)31-21(27)11-8-29-20(17(11)23)19(16)26/h8,12-13,15H,5-7,9H2,1-4H3/t12-,13+,15+,22-,23-/m0/s1QDLHCMPXEPAAMD-QAIWCSMKSA-N312145CC(=O)OC1CC2(C(CCC2=O)C3=C1C4(C(OC(=O)C5=COC(=C54)C3=O)COC)C)C
299WP1130C19H18BrN3O384.26972DUBV Kapuria (2011) Cell Signal 23(12) 2076-2085.V Kapuria (2010) Cancer Res 70(22) 9265-9276InChI=1S/C19H18BrN3O/c1-2-7-17(14-8-4-3-5-9-14)23-19(24)15(13-21)12-16- 10-6-11-18(20)22-16/h3-6,8-12,17H,2,7H2,1H3,(H,23,24)/b15-12+/t17-/m0/s1LIDOPKHSVQTSJY-VMEIHUARSA-N11222830CCC[C@@H](C1=CC=CC=C1)NC(=O)/C(=C/C2=NC(=CC=C2)Br)/C#N
127Wyeth PDK1 Inhibitor Compound 1C19H22Cl4N4O2480.21PDK1Gopalsamy A. (2007) Journal of Medicinal Chemistry 50 (23) 5547-5549
128Y-27632C14H21N3O • 2HCl • H2O338.3ROCK Watanabe K. (2007) Nature Biotech. 25 681Chitaley K. (2001) Nat. Med. 7 119Merck (Calbiochem)146986-50-7InChI=1S/C14H21N3O/c1-10(15)11-2-4-12(5-3-11)14(18)17-13-6-8-16-9-7-13/h6-12H,2-5,15H2,1H3,(H,16,17,18)/t10-,11?,12?/m1/s1IYOZTVGMEWJPKR-VOMCLLRMSA-N448042CC(C1CCC(CC1)C(=O)NC2=CC=NC=C2)N
129ZearalenoneC18H22O5318.4Estrogen receptor (ER)Powell-Jones W. (1981) Mol. Pharmacol. 20 35-42Sigma17924-92-4InChI=1S/C18H22O5/c1-12-6-5-9-14(19)8-4-2-3-7-13-10-15(20)11-16(21)17(13)18(22)23-12/h3,7,10-12,20-21H,2,4-6,8-9H2,1H3/b7-3+/t12-/m0/s1MBMQEIFVQACCCH-QBODLPLBSA-N5281576CC1CCCC(=O)CCCC=CC2=CC(=CC(=C2C(=O)O1)O)O
130ZM 336372C23H23N3O3389.4c-RafHall-Jackson C.A. (1999) Chem. Biol. 6 559Merck (Calbiochem)208260-29-1InChI=1S/C23H23N3O3/c1-15-7-10-18(24-23(29)17-5-4-6-19(13-17)26(2)3)14-21(15)25-22(28)16-8-11-20(27)12-9-16/h4-14,27H,1-3H3,(H,24,29)(H,25,28)PYEFPDQFAZNXLI-UHFFFAOYSA-N5730CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)N(C)C)NC(=O)C3=CC=C(C=C3)O